Precigen (PGEN) 10-K 1 Mar 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Feb. 15, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	PRECIGEN, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, No Par Value
Trading Symbol	PGEN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 790.4
Entity Common Stock, Shares Outstanding (in shares)		206,931,842
Documents Incorporated by Reference	Portions of the registrant's Definitive Proxy Statement for its 2022 Annual Meeting of Shareholders are incorporated by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2021.
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0001356090

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	Deloitte & Touche LLP
Auditor Location	Baltimore, Maryland
Auditor Firm ID	34

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 42,920	$ 51,792
Short-term investments	72,240	48,325
Receivables
Trade, less allowance for credit losses of $4,288 and $4,825 as of December 31, 2021 and 2020, respectively	20,832	16,487
Related parties, less allowance for credit losses of $1,509 as of December 31, 2021 and 2020	73	19
Notes	0	3,689
Other	566	232
Inventory	13,261	11,359
Prepaid expenses and other	6,736	7,192
Current assets held for sale or abandonment	0	9,853
Total current assets	156,628	148,948
Long-term investments	48,562	0
Property, plant and equipment, net	34,315	34,924
Intangible assets, net	54,115	65,396
Goodwill	54,148	54,363
Right-of-use assets	10,900	9,353
Other assets	1,188	1,603
Total assets	359,856	314,587
Current liabilities
Accounts payable	5,405	4,598
Accrued compensation and benefits	11,223	8,097
Other accrued liabilities	11,595	9,549
Deferred revenue	4,442	2,800
Current portion of long-term debt	402	360
Current portion of lease liabilities	1,551	2,657
Related party payables	27	19
Current liabilities held for sale or abandonment	0	14,047
Total current liabilities	34,645	42,127
Long-term debt, net of current portion	182,749	171,522
Deferred revenue, net of current portion, including $21,205 from related parties as of December 31, 2021 and 2020	23,023	23,023
Lease liabilities, net of current portion	9,502	7,744
Deferred tax liabilities	2,539	2,897
Other long-term liabilities	50	100
Total liabilities	252,508	247,413
Commitments and Contingencies
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of December 31, 2021 and 2020; and 206,739,874 shares and 187,663,207 shares issued and outstanding as of December 31, 2021 and 2020, respectively	0	0
Additional paid-in capital	2,022,701	1,886,567
Accumulated deficit	(1,915,556)	(1,823,390)
Accumulated other comprehensive income	203	3,997
Total shareholders' equity	107,348	67,174
Total liabilities and shareholders' equity	$ 359,856	$ 314,587

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Accounts receivable, allowance for credit loss, current	$ 4,288	$ 4,825
Related party receivable, allowance for credit loss, current	1,509	1,509
Long-term portion of deferred revenue	$ 23,023	$ 23,023
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	206,739,874	187,663,207
Common stock, shares outstanding (in shares)	206,739,874	187,663,207
Related Parties, Aggregated
Related Party Transaction [Line Items]
Long-term portion of deferred revenue	$ 21,205	$ 21,205

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Revenues	$ 103,873	$ 103,178	$ 90,722
Operating Expenses
Impairment of goodwill	0	9,635	87,862
Impairment of other noncurrent assets	543	13,326	32,627
Other Expense, Net
Unrealized and realized appreciation in fair value of equity securities and preferred stock, net	0	(106)	7,833
Equity in net loss of affiliates	(3)	(1,176)	(6,730)
Loss from continuing operations before income taxes	(96,925)	(103,855)	(171,264)
Income tax benefit	160	82	930
Income (loss) from discontinued operations, net of income tax benefit	4,599	(66,748)	(153,582)
Net loss	(92,166)	(170,521)	(323,916)
Net loss attributable to the noncontrolling interests	0	0	1,592
Net loss attributable to Precigen	(92,166)	(170,521)	(322,324)
Amounts Attributable to Precigen
Net loss from continuing operations attributable to Precigen	(96,765)	(103,773)	(168,742)
Net income (loss) from discontinued operations attributable to Precigen	4,599	(66,748)	(153,582)
Net loss attributable to Precigen	$ (92,166)	$ (170,521)	$ (322,324)
Net Loss per Share
Net loss from continuing operations attributable to Precigen per share, basic (in usd per share)	$ (0.49)	$ (0.62)	$ (1.09)
Net loss from continuing operations attributable to Precigen per share, diluted (in usd per share)	(0.49)	(0.62)	(1.09)
Net income (loss) from discontinued operations attributable to Precigen per share, basic (in usd per share)	0.02	(0.40)	(1)
Net income (loss) from discontinued operations attributable to Precigen per share, diluted (in usd per share)	0.02	(0.40)	(1)
Net loss attributable to Precigen per share, diluted (in usd per share)	(0.47)	(1.02)	(2.09)
Net loss attributable to Precigen per share, basic (in usd per share)	$ (0.47)	$ (1.02)	$ (2.09)
Weighted average shares outstanding, basic (in shares)	197,759,900	167,065,539	154,138,774
Weighted average shares outstanding, diluted (in shares)	197,759,900	167,065,539	154,138,774
Collaboration and licensing agreements
Revenues
Revenues	$ 506	$ 21,208	$ 14,059
Continuing Operations
Revenues
Revenues	103,873	103,178	90,722
Operating Expenses
Research and development	50,141	41,644	66,666
Selling, general and administrative	74,122	91,704	98,634
Impairment of goodwill	0	0	29,820
Impairment of other noncurrent assets	543	920	990
Total operating expenses	183,191	189,781	257,511
Operating loss	(79,318)	(86,603)	(166,789)
Other Expense, Net
Unrealized and realized appreciation in fair value of equity securities and preferred stock, net	0	0	8,291
Interest expense	(18,891)	(18,400)	(17,666)
Interest and dividend income	1,617	2,451	3,871
Other income (expense), net	(330)	(165)	3,445
Total other expense, net	(17,604)	(16,114)	(2,059)
Equity in net loss of affiliates	(3)	(1,138)	(2,416)
Loss from continuing operations before income taxes	(96,925)	(103,855)	(171,264)
Income tax benefit	160	82	930
Loss from continuing operations	(96,765)	(103,773)	(170,334)
Continuing Operations | Collaboration and licensing agreements
Revenues
Revenues	506	21,208	14,059
Continuing Operations | Product revenues
Revenues
Revenues	27,295	24,349	23,780
Operating Expenses
Cost of product and services	24,864	28,550	31,930
Continuing Operations | Service revenues
Revenues
Revenues	75,570	56,899	51,803
Operating Expenses
Cost of product and services	33,521	26,963	29,471
Continuing Operations | Other revenues
Revenues
Revenues	$ 502	$ 722	$ 1,080

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Revenues	$ 103,873	$ 103,178	$ 90,722
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	506	21,208	14,059
Continuing Operations
Related Party Transaction [Line Items]
Revenues	103,873	103,178	90,722
Continuing Operations | Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	506	21,208	14,059
Continuing Operations | Collaboration and licensing agreements | Related Parties, Aggregated
Related Party Transaction [Line Items]
Revenues	$ 0	$ 3,053	$ 11,832

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (92,166)	$ (170,521)	$ (323,916)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(344)	6	68
Gain (loss) on foreign currency translation adjustments	(3,450)	4,502	1,087
Release of cumulative foreign currency translation adjustments to net loss from discontinued operations	0	26,957	0
Comprehensive loss	(95,960)	(139,056)	(322,761)
Comprehensive loss attributable to the noncontrolling interests	0	0	1,581
Comprehensive loss attributable to Precigen	$ (95,960)	$ (139,056)	$ (321,180)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands	Total	Total Precigen Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interests
Beginning balance at Dec. 31, 2018	$ 378,722	$ 362,855	$ 0	$ 1,722,012	$ (28,612)	$ (1,330,545)	$ 15,867
Beginning balance, shares at Dec. 31, 2018			160,020,466
Changes in Stockholders' Equity
Stock-based compensation expense	18,950	18,881		18,881			69
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	313	63		63			250
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares			1,028,144
Shares issued for accrued compensation	1,102	1,102		1,102
Shares issued for accrued compensation, shares			150,908
Shares issued as payment for services	10,446	10,446		10,446
Shares issued as payment for services, shares			2,075,362
Shares issued in public and private offerings, net of issuance costs	6,611						6,611
Adjustments for noncontrolling interests	0	(456)		(456)			456
Deconsolidation of subsidiary	(21,672)						(21,672)
Net loss	(323,916)	(322,324)				(322,324)	(1,592)
Release of cumulative translation adjustment to loss from discontinued operations	0
Other comprehensive income (loss)	1,155	1,144			1,144		11
Ending balance at Dec. 31, 2019	71,711	71,711	$ 0	1,752,048	(27,468)	(1,652,869)	$ 0
Ending balance, shares at Dec. 31, 2019			163,274,880
Changes in Stockholders' Equity
Stock-based compensation expense		18,366		18,366
Shares issued upon vesting of restricted stock units and for exercises of stock options		117		117
Shares issued upon vesting of restricted stock units and for exercises of stock options, shares			877,249
Shares issued for accrued compensation		5,100		5,100
Shares issued for accrued compensation, shares			1,955,405
Shares issued as payment for services		1,006		1,006
Shares issued as payment for services, shares			413,911
Shares issued in public and private offerings, net of issuance costs		35,000		35,000
Shares issued in public and private offerings, net of issuance costs (in shares)			5,972,696
Shares issued upon conversion of long-term debt		56,827		56,827
Shares issued upon conversion of long-term debt, shares			13,051,802
Shares issued in conjunction with settlement agreement		18,103		18,103
Stock issued in conjunction with settlement agreement, shares			2,117,264
Net loss	(170,521)	(170,521)				(170,521)
Release of cumulative translation adjustment to loss from discontinued operations	$ 26,957	26,957			26,957
Other comprehensive income (loss)		4,508			4,508
Ending balance at Dec. 31, 2020		67,174	$ 0	1,886,567	3,997	(1,823,390)
Ending balance, shares at Dec. 31, 2020	187,663,207		187,663,207
Changes in Stockholders' Equity
Stock-based compensation expense		13,904		13,904
Shares issued upon vesting of restricted stock units and for exercises of stock options		608		608
Shares issued upon vesting of restricted stock units and for exercises of stock options, shares			1,751,896
Shares issued as payment for services		577		577
Shares issued as payment for services, shares			74,771
Shares issued in public and private offerings, net of issuance costs		121,045		121,045
Shares issued in public and private offerings, net of issuance costs (in shares)			17,250,000
Net loss	$ (92,166)	(92,166)				(92,166)
Release of cumulative translation adjustment to loss from discontinued operations	$ 0
Other comprehensive income (loss)		(3,794)			(3,794)
Ending balance at Dec. 31, 2021		$ 107,348	$ 0	$ 2,022,701	$ 203	$ (1,915,556)
Ending balance, shares at Dec. 31, 2021	206,739,874		206,739,874

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (92,166)	$ (170,521)	$ (323,916)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,761	17,516	24,896
Loss on disposals of assets, net	150	4,442	3,071
Impairment of goodwill	0	9,635	87,862
Impairment of other noncurrent assets	543	13,326	32,627
Gain on sale of discontinued operations	0	(672)	0
Loss on release of cumulative foreign currency translation adjustment	0	26,957	0
Loss on settlement agreement	0	11,436	0
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	0	106	(7,833)
Noncash dividend income	0	0	(48)
Amortization of premiums (discounts) on investments, net	1,232	(699)	(1,005)
Equity in net loss of affiliates	3	1,176	6,730
Stock-based compensation expense	13,904	18,366	18,950
Shares issued as payment for services	577	1,006	10,446
Provision for credit losses	1,268	899	3,242
Accretion of debt discount and amortization of deferred financing costs	11,735	10,587	9,459
Deferred income taxes	(167)	(156)	(3,674)
Noncash (gain) loss on termination of leases	(5,831)	191	0
Other noncash items	24	35	837
Receivables:
Trade	(6,176)	2,214	(262)
Related parties	(54)	258	967
Other	(330)	1,853	(656)
Inventory	(1,903)	2,511	4,100
Prepaid expenses and other	520	(812)	(2,262)
Other assets	305	(142)	333
Accounts payable	420	(1,097)	(5,349)
Accrued compensation and benefits	2,853	(789)	5,186
Other accrued liabilities	1,850	(2,682)	(5,516)
Deferred revenue	1,656	(21,045)	7,423
Lease liabilities	97	(887)	(995)
Related party payables	8	(33)	45
Other long-term liabilities	(50)	0	(585)
Net cash used in operating activities	(55,771)	(77,021)	(135,927)
Cash flows from investing activities
Purchases of investments	(174,221)	(171,360)	(55,073)
Sales and maturities of investments	100,168	133,000	166,495
Proceeds from sales of equity securities	0	0	23,456
Investments in affiliates	0	0	(3,713)
Decrease in cash from deconsolidation of subsidiary	0	0	(7,244)
Return of investment in affiliate	0	0	125
Purchases of property, plant and equipment	(7,247)	(7,527)	(37,883)
Proceeds from sale of assets	3,006	6,484	688
Proceeds from sale of discontinued operations, net of cash sold	0	64,240	0
Proceeds from repayment of notes receivable	3,754	2,942	0
Net cash provided by (used in) investing activities	(74,540)	27,779	86,851
Cash flows from financing activities
Proceeds from issuance of shares and warrants, net of issuance costs	121,045	35,000	6,611
Advances from lines of credit	0	10,005	11,757
Repayments of advances from lines of credit	0	(11,927)	(10,301)
Proceeds from long-term debt, net of issuance costs	0	0	376
Payments of long-term debt	(466)	(490)	(618)
Proceeds from stock option and warrant exercises	608	117	313
Net cash provided by financing activities	121,187	32,705	8,138
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	217	353	(810)
Net decrease in cash, cash equivalents, and restricted cash	(8,907)	(16,184)	(41,748)
Cash, cash equivalents, and restricted cash
Beginning of year	52,250	68,434	110,182
End of year	43,343	52,250	68,434
Supplemental disclosure of cash flow information
Cash paid during the period for interest	7,155	7,202	3,751
Cash paid during the period for income taxes	36	48	50
Significant noncash activities
Fair value of stock received as consideration for collaboration agreements	0	0	4,530
Fair value of stock issued upon conversion of long-term debt	0	56,827	0
Fair value of stock issued in conjunction with settlement agreement	0	18,103	0
Accrued compensation paid in equity awards	0	5,100	1,102
Purchases of property and equipment included in accounts payable and other accrued liabilities	820	277	694
Proceeds from sale of assets included in receivables	$ 14	$ 4,227	$ 0

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Reconciliation of Cash) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 42,920	$ 51,792
Restricted cash included in other assets	423	458
Cash, cash equivalents, and restricted cash	$ 43,343	$ 52,250

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland. Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium. Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa. Trans Ova Genetics, L.C., including its wholly owned subsidiary Progentus, L.C., are providers of reproductive technologies, including services and products sold to cattle breeders and other producers and are herein after collectively referred to as "Trans Ova." Trans Ova is a wholly owned subsidiary with primary operations in California, Iowa, Maryland, Missouri, Texas, Washington, and Wisconsin. Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform ("MBP") assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and had substantially completed the wind down by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion. Through April 8, 2019, Precigen consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Precigen no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Precigen deconsolidated AquaBounty resulting in a loss on deconsolidation of $2,648, which is included in other income, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. After deconsolidating the entity in April 2019, Precigen held its AquaBounty equity securities, which was an equity method investment that the Company accounted for using the fair value option, until October 2019 when the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security, LLC ("Third Security"), a related party, for $21,587, resulting in the recognition of a realized gain of $7,348 which is included in unrealized and realized appreciation in fair value of equity securities and preferred stock, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. On January 31, 2020, Precigen completed the sale of the majority of its non-healthcare assets and operations to an affiliate of Third Security, which are presented as discontinued operations for all periods presented. See Notes 3 and 13 for further discussion. Precigen and its consolidated subsidiaries are hereinafter collectively referred to as the "Company." Liquidity Management believes that existing liquid assets as of December 31, 2021, will allow the Company to continue its operations for at least a year from the issuance date of these consolidated financial statements. These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of therapeutic product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development, and clinical manufacturing of its therapeutic product candidates. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2021, the Company incurred a net loss of $92,166 and, as of December 31, 2021, had an accumulated deficit of $1,915,556. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, adequately satisfy or renegotiate long-term debt obligations, obtain regulatory approval of its therapeutics product candidates, successfully commercialize its therapeutics product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated. Risks and Uncertainties COVID-19 has had and continues to have an extensive impact on the global health and economic environments. Commencing in the second half of March 2020, the Company's healthcare business began to experience delays to certain of its clinical trials as a result of COVID-19. For example, starting in March 2020, the Company temporarily suspended the last cohort of the Phase 1b/2a clinical trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, its employees, and contractors. The temporary suspension of the AG019 trial was voluntary and was not related to any patient safety issues in the study. The voluntary suspension of the AG019 trial was lifted in June 2020, and recruitment in the study resumed. Additionally, from April to May 2020, enrollment of new patients in the Company's PRGN-3005 Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. The temporary suspension of the PRGN-3005 trial was not related to safety issues in the studies, and in May 2020, recruitment resumed in the PRGN-3005 Phase 1 trial. Furthermore, there is uncertainty regarding the duration and severity of the ongoing pandemic, and the Company could experience further delays or other pandemic-related events that may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future. The Company is closely monitoring the impact of COVID-19 on these and other aspects of its business, including Trans Ova and Exemplar. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses. See Note 3 for further discussion of the impact of COVID-19 on MBP Titan. Revenue Recognition The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations. Collaboration and licensing revenues The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days. The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement. At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606. The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company. From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue. Product and service revenues The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. The Company evaluates each promised product or service under its contracts and identifies performance obligations for each distinct product or service. The Company then allocates the transaction price of the contract to each performance obligation, recognizing the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized. Research and Development The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses. The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December 31, 2021 and 2020, the Company had research and development commitments with third parties that had not yet been incurred totaling $22,301 and $12,054, respectively. The commitments are generally cancellable by the Company at any time upon written notice. Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer. As of December 31, 2021 and 2020, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $20,697 and $30,164, respectively, which is included in cash and cash equivalents in the accompanying consolidated balance sheets. Short-term and Long-Term Investments As of December 31, 2021, short-term and long-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard & Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer. Equity Securities The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 17 for additional discussion of certain equity securities. For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter. Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1: Quoted prices in active markets for identical assets and liabilities; Level 2: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available. Concentrations of Risk Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2021, gross unrealized losses on the Company's short-term and long-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company manages credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable. Equity Method Investments The Company accounts for its investments in each of its joint ventures ("JVs") and accounted for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. See additional discussion related to certain of the Company's JVs in Note 4 and additional discussion related to certain of the Harvest start-up entities in Note 17. Variable Interest Entities The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. As of December 31, 2021 and 2020, the Company determined that certain of its collaborators and JVs were VIEs. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. As of December 31, 2021 and 2020, the Company had no risk of loss related to the identified VIEs. See Note 4 for discussion of the Company's future funding commitments for its significant JVs. Accounts Receivable The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted. Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available. The following table shows the activity in the allowance for credit losses for the years ended December 31, 2021, 2020, and 2019: 2021 2020 2019 Beginning balance $ 6,334 $ 7,513 $ 4,991 Charged to operating expenses 1,268 899 3,384 Write offs of accounts receivable, net of recoveries (1,805) (2,078) (862) Ending balance $ 5,797 $ 6,334 $ 7,513 Inventory The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows: Years Land improvements 4–15 Buildings and building improvements 3–23 Furniture and fixtures 1–7 Equipment 1–9 Breeding stock 1–4 Computer hardware and software 1–7 Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one Operating Leases The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term. Goodwill Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required. If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary. The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review. When the Company performs quantitative evaluations, the fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium. See Notes 3 and 10 for additional discussion regarding goodwill impairment charges recorded in the years ended December 31, 2020 and 2019. Intangible Assets Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization. The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three Impairment of Long-Lived Assets Long-lived assets to be held and used, including property, plant and equipment, ROU Assets, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. See Notes 3 and 9 for additional discussion of impairment of long-lived assets for the years ended December 31, 2021, 2020, and 2019. Convertible Notes The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option. See Note 11 for the further discussion of the Convertible Notes. Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses. The Company accounts for the minimum tax on global intangibl

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations MBP Titan As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially completed by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. This discontinuation of operations represented the continuation of a strategic shift to becoming primarily a healthcare company advancing technologies and products that address complex healthcare challenges that the Company commenced as part of the Transactions defined and discussed below. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are classified and presented as discontinued operations in the accompanying consolidated financial statements for all periods. The January 2021 sale of property and equipment resulted in a gain on disposal of assets of $464, which is included in income from discontinued operations in the accompanying consolidated statement of operations for the year ended December 31, 2021. In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility that were originally due to expire in July 2025. This lease termination resulted in a gain of $4,602, which is also included in income from discontinued operations in the accompanying consolidated statement of operations for the year ended December 31, 2021. After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners, LLC ("Intrexon Energy Partners") and Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), including the associated deferred revenue remaining under each collaboration agreement (Notes 4 and 5), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying consolidated financial statements for all periods presented as a result of the Company's continuing involvement. The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale or abandonment related to MBP Titan as of December 31, 2021 and 2020, are as follows: December 31, 2021 2020 Assets Property, plant and equipment, net $ — $ 586 Right-of-use assets — 9,131 Other assets — 136 Total assets held for sale or abandonment $ — $ 9,853 Liabilities Lease liabilities, current $ — $ 1,890 Other current liabilities — 619 Lease liabilities, net of current portion — 11,538 Total liabilities held for sale or abandonment $ — $ 14,047 The following table presents the financial results of discontinued operations related to MBP Titan: Year Ended December 31, 2021 2020 2019 Operating (gains) expenses (1) $ (4,599) $ 40,692 $ 37,423 Operating income (loss) 4,599 (40,692) (37,423) Income (loss) before income taxes 4,599 (40,692) (37,423) Income (loss) from discontinued operations $ 4,599 $ (40,692) $ (37,423) (1) Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 in 2020 in conjunction with the suspension of MBP Titan's operations discussed above. The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan that are included in the accompanying consolidated statements of cash flows. Year Ended December 31, 2021 2020 2019 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 2,474 $ 3,647 Impairment of goodwill — 9,635 — Impairment of other noncurrent assets — 12,406 — (Gain) loss on disposal of assets, net (464) 67 (316) Stock-based compensation expense — (34) 1,345 Noncash gain on termination of leases (4,602) — — Cash flows from investing activities Purchases of property, plant and equipment — (88) (2,114) Proceeds from sales of assets 1,083 3,952 29 Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc. On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's non-healthcare assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities that were directly related to the subsidiaries sold: • Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc.; • Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which focused on biological insect solutions; • ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds; and • Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations that were previously an operating division within Precigen. Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions". The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represented a strategic shift of the Company towards the Company becoming primarily a healthcare company advancing technologies and products that address complex healthcare challenges. The operations related to the Transactions have been classified and presented as discontinued operations in the accompanying consolidated financial statements for all periods. Immediately prior to the reclassification to discontinued operations in 2019, the Company evaluated goodwill, long-lived assets, and the equity method investment included in the Transactions for impairment. The Company recorded an impairment charge of $79,396, including $58,042 and $21,354 related to goodwill and other long-lived assets, respectively, at the Okanagan, Oxitec, Fine Chemicals, and AgBio reporting units. Additionally, the Company recorded a $10,283 impairment charge for the write down of the equity method investment and related intangible assets included in the EnviroFlight Sale. These impairment charges are included in loss from discontinued operations in the accompanying consolidated statement of operations for the year ended December, 31, 2019. Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $26,957 were released to earnings and included in loss from discontinued operations. See further discussion below regarding this out-of-period adjustment. The following tables present the financial results of discontinued operations related to the Transactions for the year ended December 31, 2020 and 2019. There were no discontinued operations related to the Transactions for the year ended December 31, 2021. Year Ended December 31, 2020 TS Biotechnology Sale EnviroFlight Sale Total Revenues (1) $ 1,294 $ — $ 1,294 Operating expenses 896 — 896 Operating income 398 — 398 Gain on sale of discontinued operations 633 39 672 Loss on release of cumulative foreign currency translation adjustment (26,957) — (26,957) Other expense, net (129) — (129) Equity in net loss of affiliates — (38) (38) Income (loss) before income taxes (26,055) 1 (26,054) Income tax expense (2) — (2) Income (loss) from discontinued operations $ (26,057) $ 1 $ (26,056) (1) Includes revenue recognized from related parties of $436. Year Ended December 31, 2019 TS Biotechnology Sale EnviroFlight Sale Total Revenues (1) $ 12,307 $ — $ 12,307 Operating expenses (2) 116,091 10,794 126,885 Operating loss (103,784) (10,794) (114,578) Other expense, net (272) — (272) Equity in net loss of affiliates — (4,314) (4,314) Loss before income taxes (104,056) (15,108) (119,164) Income tax benefit 3,005 — 3,005 Loss from discontinued operations $ (101,051) $ (15,108) $ (116,159) (1) Includes revenue recognized from related parties of $3,042. (2) Includes the impairment charge of $89,679 related to the Transactions discussed above. The following table presents the significant noncash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows. Year Ended December 31, 2020 2019 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 5,107 Impairment of goodwill — 58,042 Impairment of other noncurrent assets — 31,637 Gain on sale of discontinued operations (672) — Loss on release of cumulative foreign currency translation adjustment 26,957 — Unrealized and realized depreciation on equity securities and preferred stock, net 106 458 Equity in net loss of EnviroFlight 38 4,314 Stock-based compensation expense (1,346) 2,507 Deferred income taxes — (2,710) Cash flows from investing activities Investments in EnviroFlight — (2,000) Purchases of property, plant and equipment (382) (23,326) Also see Note 13. Equity Method Investments The Company accounted for its investment in EnviroFlight using the equity method of accounting. Summarized financial data for EnviroFlight are shown in the following tables for the periods in which the Company held the equity method investment. Year Ended December 31, 2020 2019 Revenues $ 16 $ 510 Operating expenses 92 9,159 Operating loss (76) (8,649) Other, net — 21 Net loss $ (76) $ (8,628) Out-of-Period Adjustment During the year ended December 31, 2020, the Company recorded an out-of-period adjustment of $26,572 to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Sale. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Sale nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's results of operations for the years ended December 31, 2020 and 2019.

Investments in Joint Ventures

Investments in Joint Ventures	12 Months Ended
	Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, a JV formed to optimize and scale-up the Company's MBP technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December 31, 2021, the Company's remaining commitment was $4,225. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(428) and $(425) as of December 31, 2021 and 2020, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners. See Notes 3 and 16 for additional discussion regarding the Company's investment in Intrexon Energy Partners. Intrexon Energy Partners II In 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, a JV formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. Also in 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of December 31, 2021, the Company's remaining commitment was $10,000. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(435) as of December 31, 2021 and 2020, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II. See Notes 3, 16, and 17 for additional discussion regarding the Company's investment in Intrexon Energy Partners II.

Collaboration and Licensing Rev

Collaboration and Licensing Revenue	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Revenue	Collaboration and Licensing RevenueThe Company's collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2021, 2020, and 2019. Year Ended December 31, 2021 2020 2019 Alaunos Therapeutics, Inc. $ 100 $ 200 $ 2,171 Oragenics, Inc. — 3,053 (564) Intrexon Energy Partners, LLC — — 2,596 Intrexon Energy Partners II, LLC — — 1,217 Castle Creek Biosciences, Inc. 388 17,810 3,713 Harvest start-up entities (1) — — 4,862 Other 18 145 64 Total (2) $ 506 $ 21,208 $ 14,059 (1) For the year ended December 31, 2019, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. (2) Collaboration and licensing revenues recognized for the years ended December 31, 2021, 2020, and 2019, include the recognition of $397, $20,205, and $7,505, respectively, associated with upfront and milestone payments which were previously deferred. The following is a summary of the terms of the Company's significant collaborations and licensing agreements from continuing operations. Alaunos Collaborations In 2018, the Company, through its wholly owned subsidiary PGEN Therapeutics, entered into a license agreement (the "Alaunos License Agreement") with Alaunos Therapeutics, Inc., formerly known as ZIOPHARM Oncology, Inc. ("Alaunos"), which terminated and replaced the terms of the ECC agreement entered into between the Company and Alaunos in 2011, including the amendments thereto. Contemporaneously with the execution of the license agreement, Alaunos ceased to be a related party. Pursuant to the terms of the Alaunos License Agreement, the Company granted Alaunos an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i) products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii) chimeric antigen receptor ("CAR") products directed to (a) CD19 for the treatment of cancer (the "CD19 Products"), and (b) a second target, subject to certain rights as discussed in the agreement, and (iii) T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted Alaunos an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's Sleeping Beauty technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of cancer and in the HPV Field. Alaunos will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. Alaunos is required to use commercially reasonable efforts to develop and commercialize IL-12 Products, CD19 Products, and the TCR Products. The Company also granted Alaunos an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. Alaunos is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. Alaunos and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with Alaunos responsible for 80% of the development costs and receiving 80% of the operating profits, as defined in the Alaunos License Agreement, and the Company responsible for the remaining 20% of the development costs and receiving 20% of the operating profits, except that Alaunos will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program"). Under the Alaunos License Agreement, Alaunos will pay the Company an annual license fee of $100 and, in 2019, reimbursed the Company $1,000 with respect to historical Gorilla IL-12 Products. Alaunos will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed programs in various jurisdictions, totaling up to an additional $52,500 for each of four exclusively licensed programs, up to an aggregate of $210,000. In addition, Alaunos will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. Alaunos will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $100,000 in the aggregate. Alaunos will also pay the Company 20% of any sublicensing income received by Alaunos relating to the licensed products. Under the Alaunos License Agreement, the Company reacquired rights previously held by Alaunos to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to Alaunos. The Company will pay Alaunos royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $50,000. The Company also received from Alaunos reimbursement of costs incurred to transition the necessary knowledge and materials for Alaunos programs for a period of one year from the effective date (the "Transition Services"). The Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to Alaunos for such products. The Alaunos License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of the later to occur of (i) the expiration of the last to expire patent claim for a licensed product, or (ii) 12 years after the first commercial sale of a licensed product in such country. In addition, Alaunos may terminate the Alaunos License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the Alaunos License Agreement following notice of a material breach. Replacement of the original ECC with the Alaunos License Agreement was a contract modification under ASC 606 that represented the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which were limited to the Transition Services, were distinct from those under the ECC. The Company determined the new agreement had a transaction price of $1,855, the majority of which related to a portion of the deferred revenue remaining from the original ECC. The annual license payments, excluding the first such payment which was included in the transaction price, and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being received. Royalty payments from sales of Alaunos products developed pursuant to the Alaunos License Agreement will be recognized when the sales occur. The Company recognized payments from Transition Services as those services were performed and recognized the transaction price as it performed the Transition Services required under the Alaunos License Agreement. The Company determined that the Gorilla Program represented a separate collaboration agreement under the scope of ASC 808, Collaborative Arrangements, ("ASC 808") and was not included in the accounting for the Alaunos License Agreement under ASC 606. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808. Oragenics Collaboration In 2015, the Company entered into an ECC with Oragenics, a related party at the time. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of the ECC, the Company received a technology access fee of a $5,000 convertible promissory note, which was subsequently converted to shares of Oragenics' common stock. These shares were sold in the TS Biotechnology Sale in 2020 (Note 3). The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. In July 2020, the Company and Oragenics mutually agreed to terminate the ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the ECC totaling $2,823. Following the termination of the ECC, Oragenics is no longer a related party. Intrexon Energy Partners Collaboration In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a JV between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's MPB technology for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The Company receives reimbursement payments for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March 2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company. The ECC is not active while the IEP Investors evaluate the status of the project and their desired future development activities. See Note 16 for additional discussion related to Intrexon Energy Partners. Intrexon Energy Partners II Collaboration In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's MBP technology for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $18,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon 90 days written notice to the Company. The ECC is not active while the IEPII Investors evaluate the status of the project and their desired future development activities. See Note 16 for additional discussion related to Intrexon Energy Partners II. Exotech Bio, AD Skincare, and Thrive Agrobiotics Collaborations In 2015 and 2016, the Company entered into three separate ECCs with Exotech Bio, Inc. ("Exotech Bio"), AD Skincare, Inc. ("AD Skincare"), and Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), all affiliates of Harvest and related parties at the time. The total upfront consideration received for the three collaborations was $11,000, which consisted of equity interests in each of these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In conjunction with a settlement agreement with Harvest (Note 17), these ECCs were terminated in December 2020, and the previously licensed technology rights reverted to the Company pursuant to the ECCs. The Company wrote off the remaining balance of deferred revenue associated with these ECCs in 2020 totaling $6,993 as an offset to the loss recognized on the settlement agreement. Castle Creek Collaborations In October 2012, the Company entered into an ECC (the "2012 Castle Creek ECC") with Castle Creek Biosciences, Inc. ("Castle Creek", formerly known as Fibrocell Science, Inc.). Castle Creek was a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until it was acquired in December 2019 by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek Pharmaceutical"), a privately held company focused on developing medicine for rare genetic disorders. Pursuant to the 2012 Castle Creek ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. The Company received (i) upfront consideration upon execution of the ECC in the form of Castle Creek common stock valued at $7,576, (ii) shares of Castle Creek common stock valued at $7,612 as consideration for a 2013 amendment which expanded the field of use defined in the agreement, (iii) sublicensing fees totaling $3,750 in the form of cash in 2019, and (iv) reimbursements for research and development services performed during the ECC. In March 2020, the Company and Castle Creek terminated the 2012 Castle Creek ECC by mutual agreement ("Termination Agreement") with the parties agreeing that the two drug product candidates, FCX-007 and FCX-013, pursuant to the ECC would be treated as "Retained Products" under the terms of the 2012 Castle Creek ECC. As Retained Products, Castle Creek retains a license under the 2012 Castle Creek ECC to continue to develop and commercialize the Retained Products within the field of use of the 2012 Castle Creek ECC for so long as Castle Creek continues to pursue such development and commercialization. No further licenses to the Company's technology within the field of use are provided to Castle Creek. On a quarterly basis, Castle Creek will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each Retained Product from the 2012 Castle Creek ECC, as defined in the agreement. Additionally, the Termination Agreement provides for the Company to perform certain drug product manufacturing activities related to the Retained Products. The Termination Agreement was accounted for as a new contract, and the remaining deferred revenue from the 2012 Castle Creek ECC was recognized prospectively through 2021 as the manufacturing activities were performed. In December 2015, the Company entered into a second ECC with Castle Creek (the "2015 Castle Creek ECC"). Pursuant to the ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. In February 2020, the Company and Castle Creek mutually agreed to terminate the 2015 Castle Creek ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the 2015 Castle Creek ECC totaling $10,000 in 2020. Deferred Revenue Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consisted of the following: December 31, 2021 2020 Collaboration and licensing agreements $ 23,023 $ 23,420 Prepaid product and service revenues 4,229 2,126 Other 213 277 Total $ 27,465 $ 25,823 Current portion of deferred revenue $ 4,442 $ 2,800 Long-term portion of deferred revenue 23,023 23,023 Total $ 27,465 $ 25,823 Revenue is recognized under collaboration and licensing agreements as services are performed. Certain of the arrangements are not active while the other party evaluates the status of the project and its desired future development activities. The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2021 and 2020, as well as the estimated remaining performance period as of December 31, 2021. Average Remaining Performance Period (Years) December 31, 2021 2020 Intrexon Energy Partners, LLC 2.2 8,362 8,362 Intrexon Energy Partners II, LLC 2.9 12,843 12,843 Castle Creek Biosciences, Inc. 0.0 — 379 Other 2.8 1,818 1,836 Total $ 23,023 $ 23,420

Short-term and Long-term Invest

Short-term and Long-term Investments	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Short-term and Long-term Investments	Short-term and Long-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021: Amortized Gross Gross Aggregate United States government debt securities $ 121,036 $ — $ (331) $ 120,705 Certificates of deposit 97 — — 97 Total $ 121,133 $ — $ (331) $ 120,802 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2020: Amortized Gross Gross Aggregate United States government debt securities $ 48,048 $ 14 $ (1) $ 48,061 Certificates of deposit 264 — — 264 Total $ 48,312 $ 14 $ (1) $ 48,325 See Notes 2 and 7 for further discussion on the Company's method for determining the fair value of its assets. The estimated fair value of available-for-sale investments classified by their contractual maturities as of December 31, 2021 was: Due within one year $ 72,240 After one year through two years 48,562 Total $ 120,802 Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's debt security investments are not significant as of December 31, 2021.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets United States government debt securities $ — $ 120,705 $ — $ 120,705 Certificates of deposit — 97 — 97 Total $ — $ 120,802 $ — $ 120,802 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2020: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets United States government debt securities $ — $ 48,061 $ — $ 48,061 Certificates of deposit — 264 — 264 Total $ — $ 48,325 $ — $ 48,325 The method used to estimate the fair value of the Level 2 short-term and long-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Liabilities The carrying values of the Company's long-term debt, excluding the Convertible Notes, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The calculated fair value of the Convertible Notes (Note 11) was approximately $160,000 and $165,000 as of December 31, 2021 and 2020, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $179,882 and $168,147 as of December 31, 2021 and 2020, respectively. During the year ended December 31, 2020, the Company's contingent consideration liability related to the 2017 Agreement and Plan of Merger of GenVec, Inc., which was $585 as of December 31, 2019, was reduced to $0 as the period for potential payment of this contingent consideration expired without payment in June 2020. The contingent consideration liability was remeasured to fair value at each reporting date until the contingency was resolved, and those changes in fair value were recognized in earnings. There were no Level 3 liabilities during the year ended December 31, 2021. The changes in the fair value of the Level 3 liability during the year ended December 21, 2020 were as follows: Balance at December 31, 2019 $ 585 Change in fair value of contingent consideration recognized in selling, general, and administrative expenses (585) Balance at December 31, 2020 $ — See Notes 9 and 10 for discussion of non-recurring fair value estimates used in calculating impairment charges recorded during the years ended December 31, 2021, 2020, and 2019.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: December 31, 2021 2020 Supplies, embryos and other production materials $ 2,588 $ 2,060 Work in process 2,564 2,348 Livestock 6,310 5,047 Feed 1,799 1,904 Total inventory $ 13,261 $ 11,359

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment consist of the following: December 31, 2021 2020 Land and land improvements $ 11,118 $ 9,844 Buildings and building improvements 12,896 12,088 Furniture and fixtures 1,162 1,228 Equipment 33,584 31,150 Leasehold improvements 4,822 6,260 Breeding stock 1,000 868 Computer hardware and software 5,131 5,684 Construction and other assets in progress 3,824 2,754 73,537 69,876 Less: Accumulated depreciation and amortization (39,222) (34,952) Property, plant and equipment, net $ 34,315 $ 34,924 Depreciation expense was $6,202, $7,449, and $8,222 for the years ended December 31, 2021, 2020, and 2019, respectively. During the year ended December 31, 2021, the Company recorded impairment losses of $543, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, primarily related to a right-of-use asset at one of the Company's leased locations. During the year ended December 31, 2020, the Company recorded impairment losses of $920, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, primarily related to right-of-use assets at certain of the Company's leased locations. During the year ended December 31, 2019, the Company recorded impairment losses of $448, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, related to the impairment of property, plant and equipment in conjunction with the closing of two of its operating units during the third quarter of 2019.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020, are as follows: 2021 2020 Beginning of year $ 54,363 $ 54,119 Foreign currency translation adjustments (215) 244 End of year $ 54,148 $ 54,363 The Company had $43,643 of cumulative goodwill impairment losses as of December 31, 2021 and 2020. For the year ended December 31, 2019, during the Company's annual goodwill impairment test, the Company determined it was more-likely-than-not that the fair value of the Trans Ova reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the Trans Ova reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $29,642 goodwill impairment charge for the excess carrying value. Additionally, the Company recorded $178 of goodwill impairment in conjunction with the closing of two of its reporting units during the third quarter of 2019. See Note 18 for information regarding goodwill by reportable segment. Intangible assets consist of the following as of December 31, 2021: Weighted Average Useful Life (Years) Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how 15.9 $ 91,373 $ (38,630) $ 52,743 Customer relationships 6.4 10,850 (10,252) 598 Trademarks 8.4 5,900 (5,126) 774 Total $ 108,123 $ (54,008) $ 54,115 Intangible assets consist of the following as of December 31, 2020: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 96,927 $ (34,412) $ 62,515 Customer relationships 10,850 (9,340) 1,510 Trademarks 5,900 (4,529) 1,371 Total $ 113,677 $ (48,281) $ 65,396 Amortization expense was $7,559, $7,593, and $7,920 for the years ended December 31, 2021, 2020, and 2019, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows: 2022 $ 6,597 2023 5,431 2024 5,121 2025 5,108 2026 5,108 Thereafter 26,750 Total $ 54,115

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Lines of Credit and Long-Term Debt	Lines of Credit and Long-Term Debt Lines of Credit Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha that matures on April 1, 2022. The line of credit bears interest at the greater of the United States Prime Rate or 3.00%, and the actual rate was 3.25% as of December 31, 2021. As of December 31, 2021 and December 31, 2020, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $5,000 as of December 31, 2021. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2022. As of December 31, 2021, the line of credit bore interest at 4.00% per annum. As of December 31, 2021 and December 31, 2020, there was no outstanding balance. Long-Term Debt Long-term debt consists of the following: December 31, 2021 2020 Convertible debt $ 179,882 $ 168,147 Notes payable 3,217 3,655 Other 52 80 Long-term debt 183,151 171,882 Less current portion 402 360 Long-term debt, less current portion $ 182,749 $ 171,522 Convertible Debt Precigen Convertible Notes In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042. The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December 31, 2021. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date. If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount. As of December 31, 2021, the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $179,882. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02%. As of December 31, 2021, the unamortized long-term debt discount and debt issuance costs totaled $20,118. The components of interest expense related to the Convertible Notes were as follows: Year Ended December 31, 2021 2020 2019 Cash interest expense $ 7,000 $ 7,000 $ 7,000 Non-cash interest expense 11,735 10,587 9,459 Total interest expense $ 18,735 $ 17,587 $ 16,459 Accrued interest of $3,500 is included in other accrued liabilities on the accompanying consolidated balance sheet as of December 31, 2021. See Note 2 for additional discussion regarding the Convertible Notes. ActoBio Convertible Notes In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest. The ActoBio Notes, which accrued interest at 3.0% compounded annually ("accrued PIK interest"), matured in September 2020. The Company issued 6,293,402 shares of Precigen common stock upon conversion of the outstanding principal balance and accrued PIK interest at maturity. Interest expense was $616 and $921 for the years ended December 31, 2020 and 2019, respectively. Precigen and PGEN Therapeutics Convertible Note In December 2018, in conjunction with the Securities Purchase, Assignment and Assumption Agreement with Ares Trading S.A. ("Ares Trading"), Precigen and PGEN Therapeutics jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. In October 2020, pursuant to the terms of the Merck Note, Ares Trading voluntarily elected to convert the entire $25,000 outstanding into 6,758,400 shares of Precigen common stock. Notes Payable Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $3,217 as of December 31, 2021. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets. Future Maturities Future maturities of long-term debt as of December 31, 2021 are as follows: 2022 $ 402 2023 200,364 2024 379 2025 394 2026 410 Thereafter 1,320 Total $ 203,269

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of loss from continuing operations before income taxes are presented below: Year Ended December 31, 2021 2020 2019 Domestic $ (93,540) $ (97,313) $ (167,990) Foreign (3,385) (6,542) (3,274) Loss from continuing operations before income taxes $ (96,925) $ (103,855) $ (171,264) The components of income tax benefit from continuing operations are presented below: Year Ended December 31, 2021 2020 2019 United States federal income taxes: Deferred $ 37 $ 37 $ (561) Foreign income taxes: Current 7 74 34 Deferred (215) (204) (230) State income taxes: Deferred 11 11 (173) Income tax benefit from continuing operations $ (160) $ (82) $ (930) Income tax benefit from continuing operations for the years ended December 31, 2021, 2020, and 2019 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following: 2021 2020 2019 Computed statutory income tax benefit from continuing operations $ (20,354) $ (21,810) $ (35,965) State and provincial income tax benefit, net of federal income taxes (3,993) (5,167) (5,494) Nondeductible stock based compensation 832 5,709 10,303 Nondeductible officer compensation 1,459 728 595 Impairment of goodwill — — 273 Research and development tax incentives (958) (524) (1,772) Acquisition and internal restructuring transaction costs — — 260 United States-foreign rate differential (32) (21) (76) Other, net (46) (306) (72) (23,092) (21,391) (31,948) Change in valuation allowance for deferred tax assets 22,932 21,309 31,018 Total income tax benefit from continuing operations $ (160) $ (82) $ (930) The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December 31, 2021 and 2020, are as follows: 2021 2020 Deferred tax assets Allowance for doubtful accounts $ 1,506 $ 1,816 Inventory 370 289 Equity securities and investments in affiliates 570 570 Property, plant and equipment — 1,882 Intangible assets 69,679 74,981 Accrued liabilities 3,090 1,834 Lease liabilities 2,839 6,140 Stock-based compensation 15,227 16,402 Deferred revenue 7,300 7,423 Research and development tax credits 11,168 10,210 Net operating, capital loss, and interest expense carryforwards 301,791 275,519 Total deferred tax assets 413,540 397,066 Less: Valuation allowance 408,396 387,348 Net deferred tax assets 5,144 9,718 Deferred tax liabilities Property, plant and equipment 250 — Right-of-use assets 2,735 5,011 Long-term debt 4,698 7,604 Total deferred tax liabilities 7,683 12,615 Net deferred tax liabilities included in continuing operations $ (2,539) $ (2,897) Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December 31, 2021, 2020, and 2019 was as follows: 2021 2020 2019 Valuation allowance at beginning of year $ 387,348 $ 349,008 $ 292,217 Increase (decrease) in valuation allowance as a result of Deconsolidation of AquaBounty — — (3,504) Establishment of deferred taxes for subsidiaries included in discontinued operations — — 8,592 Current year continuing operations 22,932 21,309 31,018 Discontinued operations treated as asset sales — 7,977 10,585 Discontinued operations related to MBP Titan (1,186) 8,019 9,663 Adoption of ASC 842 — — 512 Foreign currency translation adjustment (698) 1,035 (75) Valuation allowance at end of year $ 408,396 $ 387,348 $ 349,008 In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein. The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December 31, 2021, all such limited losses applicable to Precigen, other than losses inherited via acquisition, have been fully utilized. As of December 31, 2021, approximately $42,100 of the Company's domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction. As of December 31, 2021, the Company has net operating loss carryforwards for United States federal income tax purposes of approximately $856,400 available to offset future taxable income, including approximately $603,700 generated after 2017, United States capital loss carryforwards of approximately $212,500, and federal and state research and development tax credits of approximately $11,100, prior to consideration of annual limitations that may be imposed under Section 382. Net operating loss carryforwards generated prior to 2018 will begin to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. As of December 31, 2021, the Company's foreign subsidiaries have foreign loss carryforwards of approximately $75,700, most of which do not expire. As of December 31, 2021, the Company's direct foreign subsidiaries included in continuing operations had accumulated deficits of approximately $23,100. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes. The Company and its subsidiaries do not have material unrecognized tax benefits as of December 31, 2021. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating and capital losses and research and development tax credits.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Issuances of Precigen Common Stock In January 2021, the Company closed a public offering of 17,250,000 shares of its common stock, resulting in net proceeds of $121,045, after deducting underwriting discounts and capitalizable offering expenses. Concurrent with entering into the TS Biotechnology Sale on January 1, 2020 (Note 3), the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020. See Notes 11 and 17 for discussion regarding additional issuances of Precigen common stock. Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 11), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within five The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement. Issuances of AquaBounty Common Stock In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty. Components of Accumulated Other Comprehensive Income The components of accumulated other comprehensive income are as follows: December 31, 2021 2020 Unrealized gain (loss) on investments $ (331) $ 13 Income on foreign currency translation adjustments 534 3,984 Total accumulated other comprehensive income $ 203 $ 3,997 See Note 3 for further discussion of the release of cumulative losses on foreign currency translation adjustments upon the closing of the TS Biotechnology Sale.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Payments	Share-Based PaymentsThe Company measures the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below: Year Ended December 31, 2021 2020 2019 Cost of products $ 30 $ 10 $ 20 Cost of services 172 134 220 Research and development 2,735 1,815 3,478 Selling, general and administrative 10,967 17,787 11,380 Discontinued operations — (1,380) 3,852 Total $ 13,904 $ 18,366 $ 18,950 Precigen Stock Option Plans In April 2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December 31, 2021, there were 29,683 stock options outstanding under the 2008 Plan. Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December 31, 2021, there were 27,000,000 shares authorized for issuance under the 2013 Plan, of which 11,164,186 stock options and 306,360 RSUs were outstanding and 5,813,233 shares were available for grant. In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of December 31, 2021, there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 1,066,318 stock options and 162,121 RSUs were outstanding and 1,974,662 shares were available for grant. Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have ten-year terms and vest four years from the date of grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 11,093,063 $ 27.95 6.81 Granted 1,556,575 6.52 Exercised (19,887) (3.17) Forfeited (1,236,326) (24.92) Expired (2,371,143) (38.53) Balances at December 31, 2019 9,022,282 21.94 6.10 Granted 5,693,498 10.03 Exercised (30,061) (3.88) Forfeited (976,324) (15.47) Expired (2,453,499) (26.53) Balances at December 31, 2020 11,255,896 15.53 7.25 Granted 2,058,820 7.59 Exercised (127,883) (4.75) Forfeited (305,293) (7.02) Expired (621,353) (24.61) Balances at December 31, 2021 12,260,187 14.06 6.79 Exercisable at December 31, 2021 7,078,840 16.69 5.59 Total unrecognized compensation costs related to unvested awards as of December 31, 2021 were $15,745 and are expected to be recognized over a weighted-average period of approximately 2.50 years. The weighted average grant date fair value of options granted during 2021, 2020, and 2019 was $5.57, $2.98, and $3.79, respectively. The aggregate intrinsic value of options exercised during 2021, 2020, and 2019 was $225, $51, and $66, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise. In February 2022, the Company granted a total of 3,103,500 options to employees with a total grant date fair value of approximately $5,300. These options were issued from the 2013 Plan. The following table summarizes additional information about stock options outstanding as of December 31, 2021: Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 1.55 — $ 5.95 3,290,348 $ 4.64 8.18 $ 1,329 2,031,348 $ 4.15 7.98 $ 1,327 $ 6.01 — $ 11.90 3,568,102 9.69 8.46 — 833,104 9.79 7.90 — $ 12.01 — $ 20.94 3,068,340 18.59 6.09 — 1,880,991 19.16 4.93 — $ 21.13 — $ 45.69 2,332,393 28.06 3.22 — 2,332,393 28.06 3.22 — $ 47.35 1,004 47.35 3.51 — 1,004 47.35 3.51 — 12,260,187 $ 14.06 6.79 $ 1,329 7,078,840 $ 16.69 5.59 $ 1,327 The following table summarizes additional information about stock options outstanding as of December 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 1.55 — $ 5.95 3,259,685 $ 4.63 8.92 $ 18,157 1,271,310 $ 3.11 8.73 $ 9,018 $ 6.06 — $ 15.09 2,261,216 11.01 8.23 1,325 345,788 9.09 4.76 689 $ 15.80 — $ 20.94 3,028,309 18.85 7.38 — 1,216,258 19.82 5.62 — $ 21.13 — $ 36.84 2,303,371 26.33 4.32 — 2,200,996 26.52 4.22 — $ 37.88 — $ 47.35 403,315 42.26 4.01 — 403,315 42.26 4.01 — 11,255,896 $ 15.53 7.25 $ 19,482 5,437,667 $ 19.61 5.61 $ 9,707 RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 970,341 $ 13.82 1.43 Granted 2,278,460 6.59 Vested (1,159,165) (8.74) Forfeited (307,654) (8.99) Balances at December 31, 2019 1,781,982 8.71 1.24 Granted 3,157,390 3.09 Vested (2,802,593) (3.99) Forfeited (409,067) (8.59) Balances at December 31, 2020 1,727,712 6.11 0.42 Granted 462,019 7.87 Vested (1,624,013) (5.76) Forfeited (97,237) (8.96) Balances at December 31, 2021 468,481 8.47 0.33 Total unrecognized compensation costs related to unvested RSU awards as of December 31, 2021 were $1,145 and are expected to be recognized over a weighted-average period of approximately 0.50 years. Precigen currently uses authorized and unissued shares to satisfy share award exercises. The Company's Executive Chairman ("Executive Chairman"), who previously served as an employee and executive officer until September 24, 2020, received a base salary of $200 per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale. In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman consisting of (i) an annual retainer of $100 payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully vested stock options having a grant date fair value of $250; and (iii) an annual grant of RSUs having a grant date fair value of $250 vesting over one year. The new compensation arrangement began in calendar year 2021 and was prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. Expense associated with the arrangements above is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $680, $767, and $1,868 for the years ended December 31, 2021, 2020, and 2019, respectively.

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Operating Leases	Operating Leases The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of less than one . The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions. The components of lease costs were as follows: Year Ended December 31, 2021 2020 2019 Operating lease costs $ 3,264 $ 3,578 $ 3,821 Short-term lease costs 1,949 1,763 2,042 Variable lease costs 853 842 845 Lease costs $ 6,066 $ 6,183 $ 6,708 As of December 31, 2021, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2022 $ 2,680 2023 2,304 2024 2,355 2025 2,263 2026 1,787 Thereafter 4,638 Total 16,027 Present value adjustment (4,974) Total $ 11,053 Current portion of operating lease liabilities $ 1,551 Long-term portion of operating lease liabilities 9,502 Total $ 11,053 Other information related to operating leases in continuing operations was as follows: December 31, 2021 2020 Weighted average remaining lease term (years) 6.65 4.21 Weighted average discount rate 10.99 % 10.27 % Year Ended December 31, 2021 2020 2019 Supplemental disclosure of cash flow information Cash paid for operating lease liabilities $ 3,598 $ 4,012 $ 3,877 Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases) 4,868 417 1,137

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies On December 1, 2020, Trans Ova settled one of two patent infringement lawsuits brought by XY, LLC ("XY"). The lawsuit, originally filed in 2012, was tried and appealed between 2016 and 2020. On December 1, 2020, the parties reached a settlement resolving all remaining disputes. As part of that settlement, Trans Ova remitted to XY a settlement payment, which, in addition to all the other monies Trans Ova had previously paid XY, constituted full payment and satisfaction of the judgment, including pre-judgment interest, post-judgment interest, costs, and all past, current and future royalty obligations under the judgment. In exchange, XY released and forever discharged Trans Ova from all obligations arising out of the judgment. A second patent infringement lawsuit brought on by XY was filed in December 2016. There are currently five patents remaining at issue in the case. The Company expects the trial to occur sometime in early 2023. While this patent infringement lawsuit is pending, Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of district court and appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. In September 2020, the Company reached a final settlement with the SEC with respect to an investigation concerning the Company's disclosures regarding its MBP program in the first three quarters of 2017. Under the terms of the settlement, the Company, without admitting or denying the allegations of the SEC, consented to the entry of an administrative order requiring that the Company: (i) cease and desist from committing or causing any violations and future violations under Section 13(a) of the Securities Exchange Act of 1934, as amended, and Rules 13a-11 and 12b-20 promulgated thereunder; and (ii) pay a $2,500 civil money penalty to the SEC. In October 2020, several purported shareholder class action lawsuits were filed in the United States District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiffs' claims track the allegations in the SEC's administrative order described above but challenge disclosures about the MBP program through September 2020, i.e., the date of the SEC administrative order. The plaintiffs seek compensatory damages, interest, and an award of reasonable attorneys' fees and costs. In April 2021, the court granted an order consolidating the claims and appointed a lead plaintiff and lead counsel in the case, captioned Abailla v. Precigen, Inc., F/K/A Intrexon Corp., et al . In May 2021, the lead plaintiff filed an amended complaint. The defendants moved to dismiss that complaint. In September 2021, the court issued an order mooting the defendants' motion to dismiss in light of the lead plaintiff's stated intent to file a second amended complaint in response to the motion to dismiss. On September 27, 2021, the lead plaintiff filed a second amended complaint. The defendants intend to move to dismiss that complaint. In December 2020, a derivative shareholder action, captioned Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al , was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. asserting similar claims under state law against Precigen's current directors and certain officers. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The case was stayed by an order entered on June 14, 2021. On September 24, 2021, an individual shareholder filed a lawsuit in the Circuit Court for Henrico County styled Kent v. Precigen, Inc. , Case CL21-6349. The Kent action demands inspection of certain books and records of the Company pursuant to Virginia statutory and common law. On December 9, 2021, the Company filed a demurrer to the plaintiff's amended petition in that action. The parties have completed briefing on the demurrer and argument is scheduled for April 1, 2022. The Company intends to defend the class action lawsuit and derivative actions vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits. The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including certain IEP Investors and IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, in 2019, the Company fully reserved the amount of any disputed accounts receivable that remained outstanding. On December 29, 2021, the Company received a letter from a group of investors in each of Intrexon Energy Partners and Intrexon Energy Partners II, purporting to refer certain issues to arbitration pursuant to the arbitration provisions of the Amended and Restated Limited Liability Company Agreements of Intrexon Energy Partners and Intrexon Energy Partners II. No specific damages amount is alleged or demanded. On January 25, 2022, the Company filed a petition in the Court of Chancery for the State of Delaware seeking to join the arbitration proceeding. A hearing on the petition is scheduled for March 3, 2022, and the Company expects a decision from the Court of Chancery thereafter. Such disagreements and disputes result in management distraction and may result in further litigation, arbitration, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company's business or operations. The Company does not believe that any potential losses related to disputes with collaborators and JV partners are probable, nor estimable, at this time and has not accrued for any potential future losses, although such potential future losses could be material. In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2021, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns 100% of the equity interests of Third Security. Through December 2019, the Company was party to a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. Under the Services Agreement, as consideration for providing these services, Third Security was entitled to a fee paid in the form of fully-vested shares of Precigen common stock that approximated $800 per month. In 2019, the number of shares of common stock was calculated based on the volume weighted average of the closing price of the Company's common stock over the 30-day period ending on the 15th day of the calendar month when the applicable services were provided. During the year ended December 31, 2019, the Company issued 1,606,062 shares, with a value of $8,233, to Third Security as payment for services rendered pursuant to the Services Agreement. Following the expiration of the Services Agreement, the Company entered into a new agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company which expired on December 31, 2021. As the Company evaluates its alternatives, it continues to utilize these services on a limited basis under the terms of the original agreement. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf prior to and after the expiration of the Services Agreement under a separate agreement. The total expenses incurred by the Company under these arrangements were $100, $159, and $26 for the years ended December 31, 2021, 2020, and 2019, respectively. See also Note 14 regarding compensation arrangements between the Company and its Executive Chairman. Through November 2021, the Company also subleased certain administrative offices to Third Security. The significant terms of the lease mirrored the terms of the Company's lease with the landlord, and the Company recorded sublease income of $75, $83, and $89 for the years ended December 31, 2021, 2020, and 2019, respectively. During November 2021, in conjunction with the early termination of the sublease, Third Security paid the Company $143 which represented a pro rata portion of the early termination fee the Company paid the landlord. See Notes 1, 3, and 13 regarding additional transactions with affiliates of Third Security. Transactions with ECC Parties Collaborators in which the Company holds more than a de minimis equity interest, including interests received as upfront or milestone payments through collaborations, are considered related parties. The Company held Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), a convertible note, common shares of Castle Creek, and warrants to purchase shares of Castle Creek common stock previously acquired through collaborations and other transactions. As a result of the acquisition of Castle Creek by Castle Creek Pharmaceutical in December 2019, the Company received $1,280 in December 2019 for its shares of Castle Creek common stock and received a total of $3,311 in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. The Company recognized a total gain of $3,222 on the change in fair value of these instruments, which is included in total other expense, net, in the accompanying consolidated statement of operations for the year ended December 31, 2019. Subsequent to the acquisition by Castle Creek Pharmaceutical, Castle Creek is no longer a related party. Other Related Parties In December 2020, the Company entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and to settle all claims made in connection with the notice of arbitration noted above. Pursuant to the settlement agreement, the Company issued 2,117,264 shares of its common stock to Harvest valued at $18,103 in consideration of (i) the termination of the ECC agreements with Thrive Agrobiotics, Exotech Bio, and AD Skincare, which the Company had $6,993 of deferred revenue remaining related to these ECCs prior to the settlement agreement; (ii) the return of the Company's ownership interest in these Harvest start-up entities that had a total value of $326 prior to the settlement agreement; (iii) the commitment of Harvest (which is still ongoing) to take reasonable commercial efforts to transfer to the Company its membership interests in Intrexon Energy Partners II; and (iv) mutual irrevocable and unconditional releases of claims. The Company wrote off the investment balances and netted the deferred revenue balances associated with the eliminated service obligation against the consideration paid, resulting in a loss on the settlement agreement of $11,436 which is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2020. Outstanding receivables from these Harvest start-up entities related to research and development services performed by the Company under the ECC agreements, which had been fully reserved in 2019, were also forgiven as part of the settlement agreement and written off by the Company. Following the settlement agreement, these Harvest start-up entities are no longer related parties.

Segments

Segments	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segments	Segments The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net loss of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates but includes proceeds from the sale of assets in the period sold. During the year ended December 31, 2021, the Company modified the current period definition of Segment Adjusted EBITDA to exclude the gain or loss on disposals of assets and include proceeds from the sale of assets in the period sold. Segment Adjusted EBITDA for the years ended December 31, 2020 and 2019, were restated to reflect this change. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3). For the year ended December 31, 2021, the Company's reportable segments were (i) Biopharmaceuticals, (ii) Exemplar, and (iii) Trans Ova. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December 31, 2021. See Note 2 for a description of Biopharmaceuticals. See Note 1 for a description of Exemplar and Trans Ova. The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately. Segment Adjusted EBITDA by reportable segment was as follows: Year Ended December 31, 2021 2020 2019 Biopharmaceuticals $ (45,754) $ (35,378) $ (44,552) Exemplar 6,898 4,004 (1,586) Trans Ova 17,420 13,530 (2,836) All Other — — (3,501) Segment Adjusted EBITDA for operating segments $ (21,436) $ (17,844) $ (52,475) The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Year Ended December 31, 2021 2020 2019 Segment Adjusted EBITDA for reportable segments $ (21,436) $ (17,844) $ (48,974) All Other Segment Adjusted EBITDA — — (3,501) Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates 5,774 389 11,886 Add recognition of previously deferred revenue associated with upfront and milestone payments 2,034 25,005 14,721 Other expenses: Interest expense (18,891) (18,400) (17,666) Depreciation and amortization (13,761) (15,042) (16,142) Loss from disposals of assets (614) (4,375) (3,018) Impairment losses (543) (920) (30,810) Loss on settlement agreement — (11,436) — Stock-based compensation expense (13,904) (19,746) (15,098) Adjustment related to accrued bonuses paid in equity awards — 2,833 — Equity in net loss of affiliates (3) (1,138) (2,416) Other (19) 11 67 Unallocated corporate costs (33,506) (37,479) (46,007) Eliminations (2,056) (5,713) (14,306) Consolidated net loss from continuing operations before income taxes $ (96,925) $ (103,855) $ (171,264) Revenues by reportable segment were as follows: Year Ended December 31, 2021 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 922 $ 13,345 $ 89,606 $ 103,873 Intersegment revenues 1,637 — 429 2,066 Total segment revenues $ 2,559 $ 13,345 $ 90,035 $ 105,939 Year Ended December 31, 2020 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 21,780 $ 10,158 $ 71,186 $ 103,124 Intersegment revenues 4,797 — 340 5,137 Total segment revenues $ 26,577 $ 10,158 $ 71,526 $ 108,261 Year Ended December 31, 2019 Biopharmaceuticals Exemplar Trans Ova All Other Total Revenues from external customers $ 6,259 $ 6,958 $ 68,672 $ 4,873 $ 86,762 Intersegment revenues 12,908 7 1,361 11 14,287 Total segment revenues $ 19,167 $ 6,965 $ 70,033 $ 4,884 $ 101,049 The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Year Ended December 31, 2021 2020 2019 Total segment revenues from reportable segments $ 105,939 $ 108,261 $ 96,165 Other revenues, including from other operating segments — 54 9,064 Elimination of intersegment revenues (2,066) (5,137) (14,507) Total consolidated revenues $ 103,873 $ 103,178 $ 90,722 Goodwill by reportable segment was as follows: Biopharmaceuticals Exemplar Trans Ova Total Goodwill Balances at December 31, 2019 $ 17,449 $ 20,076 $ 16,594 $ 54,119 Foreign currency translation adjustments 244 — — 244 Balances at December 31, 2020 17,693 20,076 16,594 54,363 Foreign currency translation adjustments (215) — — (215) Balances at December 31, 2021 $ 17,478 $ 20,076 $ 16,594 $ 54,148 As of December 31, 2021 and 2020, the Company had $4,463 and $5,908, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $530, $595, and $1,401 for the years ended December 31, 2021, 2020, and 2019, respectively.

Defined Contribution Plans

Defined Contribution Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined Contribution Plans	Defined Contribution PlansThe Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $887, $873, and $1,186 for the years ended December 31, 2021, 2020, and 2019, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations. Collaboration and licensing revenues The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days. The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement. At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606. The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company. From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue. Product and service revenues The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. The Company evaluates each promised product or service under its contracts and identifies performance obligations for each distinct product or service. The Company then allocates the transaction price of the contract to each performance obligation, recognizing the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.
Research and Development	Research and Development The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.
Cash and Cash Equivalents	Cash and Cash EquivalentsAll highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer.
Short-term and Long-Term Investments	Short-term and Long-Term Investments As of December 31, 2021, short-term and long-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be
Equity Securities	Equity Securities The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 17 for additional discussion of certain equity securities. For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1: Quoted prices in active markets for identical assets and liabilities; Level 2: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.
Concentrations of Risk	Concentrations of Risk Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2021, gross unrealized losses on the Company's short-term and long-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company manages credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.
Equity Method Investments	Equity Method Investments The Company accounts for its investments in each of its joint ventures ("JVs") and accounted for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity
Variable Interest Entities	Variable Interest EntitiesThe Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.
Accounts Receivables	Accounts Receivable The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted. Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.
Inventory	Inventory The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows: Years Land improvements 4–15 Buildings and building improvements 3–23 Furniture and fixtures 1–7 Equipment 1–9 Breeding stock 1–4 Computer hardware and software 1–7 one
Operating Leases	Operating Leases The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.
Goodwill	Goodwill Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required. If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary. The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review. When the Company performs quantitative evaluations, the fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the
Intangible Assets	Intangible Assets Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization. The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets to be held and used, including property, plant and equipment, ROU Assets, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
Convertible Notes	Convertible Notes The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option.
Foreign Currency Translation	Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.
Share-Based Payments	Share-Based Payments Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021, 2020, and 2019 are set forth in the table below: 2021 2020 2019 Valuation assumptions Expected dividend yield 0% 0% 0% Expected volatility 87%–90% 59%–90% 58%–64% Expected term (years) 6.00 6.00–10.00 6.25 Risk-free interest rate 0.61%–1.33% 0.36%–1.80% 1.53%–2.58%
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information	Segment Information The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. Starting in 2021, the financial information regularly reviewed by the CODM was revised, and the operating segments, which were determined to be operating and reportable segments, were (i) Biopharmaceuticals; (ii) Exemplar; and (iii) Trans Ova. The Biopharmaceuticals reportable segment is primarily comprised of the Company's legal entities of PGEN Therapeutics and ActoBio. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, Exemplar, and Trans Ova. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, gain or loss on disposals of assets, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. As a result of the revision of the reportable segments, the Company has restated its historical segment presentation to conform to the revised segment determination. See Note 18 for further discussion of the Company's segments.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. The Company adopted this standard effective January 1, 2021, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06" ) . The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The Company will adopt this standard effective January 1, 2022 on a modified retrospective basis. The Company expects the adoption of ASU 2020-06 will have an impact to its consolidated balance sheet as of January 1, 2022, increasing long-term debt, net of current portion, by approximately $18,200 to reflect the full principal amount of the Convertible Notes outstanding, net of unamortized issuance costs, with an offsetting decrease to shareholders' equity of the same amount. The adoption of ASU 2020-06 is expected to reduce non-cash interest expense by approximately

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Accounts Receivable, Allowance for Credit Losses	The following table shows the activity in the allowance for credit losses for the years ended December 31, 2021, 2020, and 2019: 2021 2020 2019 Beginning balance $ 6,334 $ 7,513 $ 4,991 Charged to operating expenses 1,268 899 3,384 Write offs of accounts receivable, net of recoveries (1,805) (2,078) (862) Ending balance $ 5,797 $ 6,334 $ 7,513
Estimated Useful Lives of Property, Plant and Equipment	The estimated useful lives of these assets from continuing operations are as follows: Years Land improvements 4–15 Buildings and building improvements 3–23 Furniture and fixtures 1–7 Equipment 1–9 Breeding stock 1–4 Computer hardware and software 1–7 one
Summary of Assumptions Used in Option Pricing Model	The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021, 2020, and 2019 are set forth in the table below: 2021 2020 2019 Valuation assumptions Expected dividend yield 0% 0% 0% Expected volatility 87%–90% 59%–90% 58%–64% Expected term (years) 6.00 6.00–10.00 6.25 Risk-free interest rate 0.61%–1.33% 0.36%–1.80% 1.53%–2.58%
Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share	The following potentially dilutive securities as of December 31, 2021, 2020, and 2019, have been excluded from the computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive: December 31, 2021 2020 2019 Convertible debt 11,732,440 11,732,440 21,323,068 Options 12,260,187 11,255,896 9,022,282 Restricted stock units 468,481 1,727,712 1,781,982 Warrants 121,888 133,264 133,264 Total 24,582,996 24,849,312 32,260,596

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale or abandonment related to MBP Titan as of December 31, 2021 and 2020, are as follows: December 31, 2021 2020 Assets Property, plant and equipment, net $ — $ 586 Right-of-use assets — 9,131 Other assets — 136 Total assets held for sale or abandonment $ — $ 9,853 Liabilities Lease liabilities, current $ — $ 1,890 Other current liabilities — 619 Lease liabilities, net of current portion — 11,538 Total liabilities held for sale or abandonment $ — $ 14,047 The following table presents the financial results of discontinued operations related to MBP Titan: Year Ended December 31, 2021 2020 2019 Operating (gains) expenses (1) $ (4,599) $ 40,692 $ 37,423 Operating income (loss) 4,599 (40,692) (37,423) Income (loss) before income taxes 4,599 (40,692) (37,423) Income (loss) from discontinued operations $ 4,599 $ (40,692) $ (37,423) (1) Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 in 2020 in conjunction with the suspension of MBP Titan's operations discussed above. The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan that are included in the accompanying consolidated statements of cash flows. Year Ended December 31, 2021 2020 2019 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 2,474 $ 3,647 Impairment of goodwill — 9,635 — Impairment of other noncurrent assets — 12,406 — (Gain) loss on disposal of assets, net (464) 67 (316) Stock-based compensation expense — (34) 1,345 Noncash gain on termination of leases (4,602) — — Cash flows from investing activities Purchases of property, plant and equipment — (88) (2,114) Proceeds from sales of assets 1,083 3,952 29 The following tables present the financial results of discontinued operations related to the Transactions for the year ended December 31, 2020 and 2019. There were no discontinued operations related to the Transactions for the year ended December 31, 2021. Year Ended December 31, 2020 TS Biotechnology Sale EnviroFlight Sale Total Revenues (1) $ 1,294 $ — $ 1,294 Operating expenses 896 — 896 Operating income 398 — 398 Gain on sale of discontinued operations 633 39 672 Loss on release of cumulative foreign currency translation adjustment (26,957) — (26,957) Other expense, net (129) — (129) Equity in net loss of affiliates — (38) (38) Income (loss) before income taxes (26,055) 1 (26,054) Income tax expense (2) — (2) Income (loss) from discontinued operations $ (26,057) $ 1 $ (26,056) (1) Includes revenue recognized from related parties of $436. Year Ended December 31, 2019 TS Biotechnology Sale EnviroFlight Sale Total Revenues (1) $ 12,307 $ — $ 12,307 Operating expenses (2) 116,091 10,794 126,885 Operating loss (103,784) (10,794) (114,578) Other expense, net (272) — (272) Equity in net loss of affiliates — (4,314) (4,314) Loss before income taxes (104,056) (15,108) (119,164) Income tax benefit 3,005 — 3,005 Loss from discontinued operations $ (101,051) $ (15,108) $ (116,159) (1) Includes revenue recognized from related parties of $3,042. (2) Includes the impairment charge of $89,679 related to the Transactions discussed above. The following table presents the significant noncash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows. Year Ended December 31, 2020 2019 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 5,107 Impairment of goodwill — 58,042 Impairment of other noncurrent assets — 31,637 Gain on sale of discontinued operations (672) — Loss on release of cumulative foreign currency translation adjustment 26,957 — Unrealized and realized depreciation on equity securities and preferred stock, net 106 458 Equity in net loss of EnviroFlight 38 4,314 Stock-based compensation expense (1,346) 2,507 Deferred income taxes — (2,710) Cash flows from investing activities Investments in EnviroFlight — (2,000) Purchases of property, plant and equipment (382) (23,326) Summarized financial data for EnviroFlight are shown in the following tables for the periods in which the Company held the equity method investment. Year Ended December 31, 2020 2019 Revenues $ 16 $ 510 Operating expenses 92 9,159 Operating loss (76) (8,649) Other, net — 21 Net loss $ (76) $ (8,628)

Collaboration and Licensing R_2

Collaboration and Licensing Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summarized Collaboration and Licensing Revenues	The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2021, 2020, and 2019. Year Ended December 31, 2021 2020 2019 Alaunos Therapeutics, Inc. $ 100 $ 200 $ 2,171 Oragenics, Inc. — 3,053 (564) Intrexon Energy Partners, LLC — — 2,596 Intrexon Energy Partners II, LLC — — 1,217 Castle Creek Biosciences, Inc. 388 17,810 3,713 Harvest start-up entities (1) — — 4,862 Other 18 145 64 Total (2) $ 506 $ 21,208 $ 14,059 (1) For the year ended December 31, 2019, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. (2) Collaboration and licensing revenues recognized for the years ended December 31, 2021, 2020, and 2019, include the recognition of $397, $20,205, and $7,505, respectively, associated with upfront and milestone payments which were previously deferred.
Summary of Deferred Revenue	Deferred revenue consisted of the following: December 31, 2021 2020 Collaboration and licensing agreements $ 23,023 $ 23,420 Prepaid product and service revenues 4,229 2,126 Other 213 277 Total $ 27,465 $ 25,823 Current portion of deferred revenue $ 4,442 $ 2,800 Long-term portion of deferred revenue 23,023 23,023 Total $ 27,465 $ 25,823
Summary of Deferred Revenue by Collaborator	The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2021 and 2020, as well as the estimated remaining performance period as of December 31, 2021. Average Remaining Performance Period (Years) December 31, 2021 2020 Intrexon Energy Partners, LLC 2.2 8,362 8,362 Intrexon Energy Partners II, LLC 2.9 12,843 12,843 Castle Creek Biosciences, Inc. 0.0 — 379 Other 2.8 1,818 1,836 Total $ 23,023 $ 23,420

Short-term and Long-term Inve_2

Short-term and Long-term Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments	The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021: Amortized Gross Gross Aggregate United States government debt securities $ 121,036 $ — $ (331) $ 120,705 Certificates of deposit 97 — — 97 Total $ 121,133 $ — $ (331) $ 120,802 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2020: Amortized Gross Gross Aggregate United States government debt securities $ 48,048 $ 14 $ (1) $ 48,061 Certificates of deposit 264 — — 264 Total $ 48,312 $ 14 $ (1) $ 48,325
Contractual Obligation, Fiscal Year Maturity	The estimated fair value of available-for-sale investments classified by their contractual maturities as of December 31, 2021 was: Due within one year $ 72,240 After one year through two years 48,562 Total $ 120,802

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets United States government debt securities $ — $ 120,705 $ — $ 120,705 Certificates of deposit — 97 — 97 Total $ — $ 120,802 $ — $ 120,802 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2020: Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets United States government debt securities $ — $ 48,061 $ — $ 48,061 Certificates of deposit — 264 — 264 Total $ — $ 48,325 $ — $ 48,325
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The changes in the fair value of the Level 3 liability during the year ended December 21, 2020 were as follows: Balance at December 31, 2019 $ 585 Change in fair value of contingent consideration recognized in selling, general, and administrative expenses (585) Balance at December 31, 2020 $ —

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: December 31, 2021 2020 Supplies, embryos and other production materials $ 2,588 $ 2,060 Work in process 2,564 2,348 Livestock 6,310 5,047 Feed 1,799 1,904 Total inventory $ 13,261 $ 11,359

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following: December 31, 2021 2020 Land and land improvements $ 11,118 $ 9,844 Buildings and building improvements 12,896 12,088 Furniture and fixtures 1,162 1,228 Equipment 33,584 31,150 Leasehold improvements 4,822 6,260 Breeding stock 1,000 868 Computer hardware and software 5,131 5,684 Construction and other assets in progress 3,824 2,754 73,537 69,876 Less: Accumulated depreciation and amortization (39,222) (34,952) Property, plant and equipment, net $ 34,315 $ 34,924

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020, are as follows: 2021 2020 Beginning of year $ 54,363 $ 54,119 Foreign currency translation adjustments (215) 244 End of year $ 54,148 $ 54,363
Schedule of Intangible Assets	Intangible assets consist of the following as of December 31, 2021: Weighted Average Useful Life (Years) Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how 15.9 $ 91,373 $ (38,630) $ 52,743 Customer relationships 6.4 10,850 (10,252) 598 Trademarks 8.4 5,900 (5,126) 774 Total $ 108,123 $ (54,008) $ 54,115 Intangible assets consist of the following as of December 31, 2020: Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 96,927 $ (34,412) $ 62,515 Customer relationships 10,850 (9,340) 1,510 Trademarks 5,900 (4,529) 1,371 Total $ 113,677 $ (48,281) $ 65,396
Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense	Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows: 2022 $ 6,597 2023 5,431 2024 5,121 2025 5,108 2026 5,108 Thereafter 26,750 Total $ 54,115

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	Long-term debt consists of the following: December 31, 2021 2020 Convertible debt $ 179,882 $ 168,147 Notes payable 3,217 3,655 Other 52 80 Long-term debt 183,151 171,882 Less current portion 402 360 Long-term debt, less current portion $ 182,749 $ 171,522
Components of Interest Expense	The components of interest expense related to the Convertible Notes were as follows: Year Ended December 31, 2021 2020 2019 Cash interest expense $ 7,000 $ 7,000 $ 7,000 Non-cash interest expense 11,735 10,587 9,459 Total interest expense $ 18,735 $ 17,587 $ 16,459
Schedule of Maturities of Long-Term Debt	Future maturities of long-term debt as of December 31, 2021 are as follows: 2022 $ 402 2023 200,364 2024 379 2025 394 2026 410 Thereafter 1,320 Total $ 203,269

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	The components of loss from continuing operations before income taxes are presented below: Year Ended December 31, 2021 2020 2019 Domestic $ (93,540) $ (97,313) $ (167,990) Foreign (3,385) (6,542) (3,274) Loss from continuing operations before income taxes $ (96,925) $ (103,855) $ (171,264)
Components of Income Tax Benefit	The components of income tax benefit from continuing operations are presented below: Year Ended December 31, 2021 2020 2019 United States federal income taxes: Deferred $ 37 $ 37 $ (561) Foreign income taxes: Current 7 74 34 Deferred (215) (204) (230) State income taxes: Deferred 11 11 (173) Income tax benefit from continuing operations $ (160) $ (82) $ (930)
Schedule of Effective Income Tax Rate Reconciliation	Income tax benefit from continuing operations for the years ended December 31, 2021, 2020, and 2019 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following: 2021 2020 2019 Computed statutory income tax benefit from continuing operations $ (20,354) $ (21,810) $ (35,965) State and provincial income tax benefit, net of federal income taxes (3,993) (5,167) (5,494) Nondeductible stock based compensation 832 5,709 10,303 Nondeductible officer compensation 1,459 728 595 Impairment of goodwill — — 273 Research and development tax incentives (958) (524) (1,772) Acquisition and internal restructuring transaction costs — — 260 United States-foreign rate differential (32) (21) (76) Other, net (46) (306) (72) (23,092) (21,391) (31,948) Change in valuation allowance for deferred tax assets 22,932 21,309 31,018 Total income tax benefit from continuing operations $ (160) $ (82) $ (930)
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December 31, 2021 and 2020, are as follows: 2021 2020 Deferred tax assets Allowance for doubtful accounts $ 1,506 $ 1,816 Inventory 370 289 Equity securities and investments in affiliates 570 570 Property, plant and equipment — 1,882 Intangible assets 69,679 74,981 Accrued liabilities 3,090 1,834 Lease liabilities 2,839 6,140 Stock-based compensation 15,227 16,402 Deferred revenue 7,300 7,423 Research and development tax credits 11,168 10,210 Net operating, capital loss, and interest expense carryforwards 301,791 275,519 Total deferred tax assets 413,540 397,066 Less: Valuation allowance 408,396 387,348 Net deferred tax assets 5,144 9,718 Deferred tax liabilities Property, plant and equipment 250 — Right-of-use assets 2,735 5,011 Long-term debt 4,698 7,604 Total deferred tax liabilities 7,683 12,615 Net deferred tax liabilities included in continuing operations $ (2,539) $ (2,897)
Summary of Valuation Allowance	Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December 31, 2021, 2020, and 2019 was as follows: 2021 2020 2019 Valuation allowance at beginning of year $ 387,348 $ 349,008 $ 292,217 Increase (decrease) in valuation allowance as a result of Deconsolidation of AquaBounty — — (3,504) Establishment of deferred taxes for subsidiaries included in discontinued operations — — 8,592 Current year continuing operations 22,932 21,309 31,018 Discontinued operations treated as asset sales — 7,977 10,585 Discontinued operations related to MBP Titan (1,186) 8,019 9,663 Adoption of ASC 842 — — 512 Foreign currency translation adjustment (698) 1,035 (75) Valuation allowance at end of year $ 408,396 $ 387,348 $ 349,008

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of accumulated other comprehensive income are as follows: December 31, 2021 2020 Unrealized gain (loss) on investments $ (331) $ 13 Income on foreign currency translation adjustments 534 3,984 Total accumulated other comprehensive income $ 203 $ 3,997

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	Stock-based compensation costs included in the consolidated statements of operations are presented below: Year Ended December 31, 2021 2020 2019 Cost of products $ 30 $ 10 $ 20 Cost of services 172 134 220 Research and development 2,735 1,815 3,478 Selling, general and administrative 10,967 17,787 11,380 Discontinued operations — (1,380) 3,852 Total $ 13,904 $ 18,366 $ 18,950
Schedule of Stock Option Activity	Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 11,093,063 $ 27.95 6.81 Granted 1,556,575 6.52 Exercised (19,887) (3.17) Forfeited (1,236,326) (24.92) Expired (2,371,143) (38.53) Balances at December 31, 2019 9,022,282 21.94 6.10 Granted 5,693,498 10.03 Exercised (30,061) (3.88) Forfeited (976,324) (15.47) Expired (2,453,499) (26.53) Balances at December 31, 2020 11,255,896 15.53 7.25 Granted 2,058,820 7.59 Exercised (127,883) (4.75) Forfeited (305,293) (7.02) Expired (621,353) (24.61) Balances at December 31, 2021 12,260,187 14.06 6.79 Exercisable at December 31, 2021 7,078,840 16.69 5.59
Summary of Information About Stock Options Outstanding	The following table summarizes additional information about stock options outstanding as of December 31, 2021: Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 1.55 — $ 5.95 3,290,348 $ 4.64 8.18 $ 1,329 2,031,348 $ 4.15 7.98 $ 1,327 $ 6.01 — $ 11.90 3,568,102 9.69 8.46 — 833,104 9.79 7.90 — $ 12.01 — $ 20.94 3,068,340 18.59 6.09 — 1,880,991 19.16 4.93 — $ 21.13 — $ 45.69 2,332,393 28.06 3.22 — 2,332,393 28.06 3.22 — $ 47.35 1,004 47.35 3.51 — 1,004 47.35 3.51 — 12,260,187 $ 14.06 6.79 $ 1,329 7,078,840 $ 16.69 5.59 $ 1,327 The following table summarizes additional information about stock options outstanding as of December 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 1.55 — $ 5.95 3,259,685 $ 4.63 8.92 $ 18,157 1,271,310 $ 3.11 8.73 $ 9,018 $ 6.06 — $ 15.09 2,261,216 11.01 8.23 1,325 345,788 9.09 4.76 689 $ 15.80 — $ 20.94 3,028,309 18.85 7.38 — 1,216,258 19.82 5.62 — $ 21.13 — $ 36.84 2,303,371 26.33 4.32 — 2,200,996 26.52 4.22 — $ 37.88 — $ 47.35 403,315 42.26 4.01 — 403,315 42.26 4.01 — 11,255,896 $ 15.53 7.25 $ 19,482 5,437,667 $ 19.61 5.61 $ 9,707
Schedule of Restricted Stock Unit Activity	RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 970,341 $ 13.82 1.43 Granted 2,278,460 6.59 Vested (1,159,165) (8.74) Forfeited (307,654) (8.99) Balances at December 31, 2019 1,781,982 8.71 1.24 Granted 3,157,390 3.09 Vested (2,802,593) (3.99) Forfeited (409,067) (8.59) Balances at December 31, 2020 1,727,712 6.11 0.42 Granted 462,019 7.87 Vested (1,624,013) (5.76) Forfeited (97,237) (8.96) Balances at December 31, 2021 468,481 8.47 0.33

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Components of Lease Costs	The components of lease costs were as follows: Year Ended December 31, 2021 2020 2019 Operating lease costs $ 3,264 $ 3,578 $ 3,821 Short-term lease costs 1,949 1,763 2,042 Variable lease costs 853 842 845 Lease costs $ 6,066 $ 6,183 $ 6,708 Other information related to operating leases in continuing operations was as follows: December 31, 2021 2020 Weighted average remaining lease term (years) 6.65 4.21 Weighted average discount rate 10.99 % 10.27 % Year Ended December 31, 2021 2020 2019 Supplemental disclosure of cash flow information Cash paid for operating lease liabilities $ 3,598 $ 4,012 $ 3,877 Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases) 4,868 417 1,137
Maturities of Lease Liabilities	As of December 31, 2021, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2022 $ 2,680 2023 2,304 2024 2,355 2025 2,263 2026 1,787 Thereafter 4,638 Total 16,027 Present value adjustment (4,974) Total $ 11,053 Current portion of operating lease liabilities $ 1,551 Long-term portion of operating lease liabilities 9,502 Total $ 11,053

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Information by Reportable Segment	Segment Adjusted EBITDA by reportable segment was as follows: Year Ended December 31, 2021 2020 2019 Biopharmaceuticals $ (45,754) $ (35,378) $ (44,552) Exemplar 6,898 4,004 (1,586) Trans Ova 17,420 13,530 (2,836) All Other — — (3,501) Segment Adjusted EBITDA for operating segments $ (21,436) $ (17,844) $ (52,475) Revenues by reportable segment were as follows: Year Ended December 31, 2021 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 922 $ 13,345 $ 89,606 $ 103,873 Intersegment revenues 1,637 — 429 2,066 Total segment revenues $ 2,559 $ 13,345 $ 90,035 $ 105,939 Year Ended December 31, 2020 Biopharmaceuticals Exemplar Trans Ova Total Revenues from external customers $ 21,780 $ 10,158 $ 71,186 $ 103,124 Intersegment revenues 4,797 — 340 5,137 Total segment revenues $ 26,577 $ 10,158 $ 71,526 $ 108,261 Year Ended December 31, 2019 Biopharmaceuticals Exemplar Trans Ova All Other Total Revenues from external customers $ 6,259 $ 6,958 $ 68,672 $ 4,873 $ 86,762 Intersegment revenues 12,908 7 1,361 11 14,287 Total segment revenues $ 19,167 $ 6,965 $ 70,033 $ 4,884 $ 101,049 Goodwill by reportable segment was as follows: Biopharmaceuticals Exemplar Trans Ova Total Goodwill Balances at December 31, 2019 $ 17,449 $ 20,076 $ 16,594 $ 54,119 Foreign currency translation adjustments 244 — — 244 Balances at December 31, 2020 17,693 20,076 16,594 54,363 Foreign currency translation adjustments (215) — — (215) Balances at December 31, 2021 $ 17,478 $ 20,076 $ 16,594 $ 54,148
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Year Ended December 31, 2021 2020 2019 Segment Adjusted EBITDA for reportable segments $ (21,436) $ (17,844) $ (48,974) All Other Segment Adjusted EBITDA — — (3,501) Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates 5,774 389 11,886 Add recognition of previously deferred revenue associated with upfront and milestone payments 2,034 25,005 14,721 Other expenses: Interest expense (18,891) (18,400) (17,666) Depreciation and amortization (13,761) (15,042) (16,142) Loss from disposals of assets (614) (4,375) (3,018) Impairment losses (543) (920) (30,810) Loss on settlement agreement — (11,436) — Stock-based compensation expense (13,904) (19,746) (15,098) Adjustment related to accrued bonuses paid in equity awards — 2,833 — Equity in net loss of affiliates (3) (1,138) (2,416) Other (19) 11 67 Unallocated corporate costs (33,506) (37,479) (46,007) Eliminations (2,056) (5,713) (14,306) Consolidated net loss from continuing operations before income taxes $ (96,925) $ (103,855) $ (171,264)
Reconciliation of Revenue from Segments to Consolidated	The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Year Ended December 31, 2021 2020 2019 Total segment revenues from reportable segments $ 105,939 $ 108,261 $ 96,165 Other revenues, including from other operating segments — 54 9,064 Elimination of intersegment revenues (2,066) (5,137) (14,507) Total consolidated revenues $ 103,873 $ 103,178 $ 90,722

Organization and Basis of Pre_2

Organization and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deconsolidation, loss, amount				$ 2,648
Proceeds from sales of equity securities	$ 21,587	$ 0	$ 0	23,456
Unrealized and realized appreciation in fair value of equity securities and preferred stock, net	$ 7,348	0	(106)	7,833
Net income (loss) attributable to parent		(92,166)	(170,521)	$ (322,324)
Accumulated deficit		$ (1,915,556)	$ (1,823,390)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2022	Jul. 31, 2018
Organization And Significant Accounting Policies [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Research and development commitments with third parties not incurred			$ 22,301	$ 12,054
Maturity period of highly liquid investment			3 months
Cash equivalent investments in highly liquid money market accounts			$ 20,697	30,164
Maximum risk of loss related to the identified VIEs			0	0
Long-term debt, net of current portion			$ 182,749	$ 171,522
Accounting Standards Update 2020-06 Retrospective | Forecast | Cumulative Effect, Period of Adoption, Adjustment
Organization And Significant Accounting Policies [Line Items]
Non-cash interest expense	$ (6,400)	$ (11,800)
Accounting Standards Update 2020-06 Retrospective | Subsequent Event | Cumulative Effect, Period of Adoption, Adjustment
Organization And Significant Accounting Policies [Line Items]
Long-term debt, net of current portion						$ 18,200
Minimum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset			3 years
Maximum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset			18 years
Precigen Stock Option Plans
Organization And Significant Accounting Policies [Line Items]
Expected dividend yield			0.00%	0.00%	0.00%
Products and services revenues
Organization And Significant Accounting Policies [Line Items]
Product and service revenues, standard payment terms			30 days
3.5% Convertible Notes Due 2023
Organization And Significant Accounting Policies [Line Items]
Debt instrument, interest rate, stated percentage							3.50%
Non-cash interest expense			$ 11,735	$ 10,587	$ 9,459

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for Credit Losses
Charged to operating expenses	$ 1,268	$ 899	$ 3,242
Continuing Operations
Allowance for Credit Losses
Beginning balance	6,334	7,513	4,991
Charged to operating expenses	1,268	899	3,384
Write offs of accounts receivable, net of recoveries	(1,805)	(2,078)	(862)
Ending balance	$ 5,797	$ 6,334	$ 7,513

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Minimum | Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Minimum | Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	3 years
Minimum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Maximum | Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	15 years
Maximum | Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	23 years
Maximum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum | Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	9 years
Maximum | Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Maximum | Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	14 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details) - Precigen Stock Option Plans	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, minimum	87.00%	59.00%	58.00%
Expected volatility, maximum	90.00%	90.00%	64.00%
Expected term (years)	6 years		6 years 3 months
Risk-free interest rate, minimum	0.61%	0.36%	1.53%
Risk-free interest rate, maximum	1.33%	1.80%	2.58%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		6 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		10 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	24,582,996	24,849,312	32,260,596
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	11,732,440	11,732,440	21,323,068
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	12,260,187	11,255,896	9,022,282
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	468,481	1,727,712	1,781,982
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	121,888	133,264	133,264

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Sep. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of goodwill		$ 178	$ 0	$ 9,635	$ 87,862
Loss on release of cumulative foreign currency translation adjustment			0	26,957	0
TS Biotechnology Holdings, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration	$ 53,000
Loss on release of cumulative foreign currency translation adjustment	$ 26,957			26,957
Discontinued operation, amount of adjustment to prior period loss on disposal, net of tax				26,572
EnviroFlight Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration						$ 12,200
Loss on release of cumulative foreign currency translation adjustment				0
EnviroFlight Sale | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge on write down of investment in affiliate				10,283
TS Biotechnology Holdings, LLC and EnviroFlight, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges					89,679
Impairment of goodwill				0	58,042
Loss on release of cumulative foreign currency translation adjustment				26,957	0
MBP Titan | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposal of assets, net			464	(67)	316
Gain on lease termination			4,602
Impairment of goodwill			0	9,635	0
Impairment of other noncurrent assets			$ 0	12,406	$ 0
Okanagan, Oxitec, Fine Chemicals, And AgBio | TS Biotechnology Holdings, LLC and EnviroFlight, LLC | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges				79,396
Impairment of goodwill				58,042
Impairment of other noncurrent assets				$ 21,354

Discontinued Operations - Carry

Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - MBP Titan - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Property, plant and equipment, net	$ 0	$ 586
Right-of-use assets	0	9,131
Other assets	0	136
Total assets held for sale or abandonment	0	9,853
Liabilities
Lease liabilities, current	0	1,890
Other current liabilities	0	619
Lease liabilities, net of current portion	0	11,538
Total liabilities held for sale or abandonment	$ 0	$ 14,047

Discontinued Operations - Summa

Discontinued Operations - Summary of Financial Results for MBP Titan (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations		$ 4,599	$ (66,748)	$ (153,582)
Impairment of goodwill	$ 178	0	9,635	87,862
MBP Titan | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Operating (gains) expenses		(4,599)	40,692	37,423
Operating income (loss)		4,599	(40,692)	(37,423)
Income (loss) before income taxes		4,599	(40,692)	(37,423)
Income (loss) from discontinued operations		4,599	(40,692)	(37,423)
Impairment of goodwill		0	9,635	0
Impairment of other noncurrent assets		$ 0	$ 12,406	$ 0

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		$ 13,761	$ 17,516	$ 24,896
Impairment of goodwill	$ 178	0	9,635	87,862
Stock-based compensation expense		13,904	18,366	18,950
Deferred income taxes		(167)	(156)	(3,674)
Noncash (gain) loss on termination of leases		(5,831)	191	0
Cash flows from investing activities
Purchases of property, plant and equipment		(7,247)	(7,527)	(37,883)
Proceeds from sale of assets		3,006	6,484	688
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment | MBP Titan
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		0	2,474	3,647
Impairment of goodwill		0	9,635	0
Impairment of other noncurrent assets		0	12,406	0
(Gain) loss on disposal of assets, net		(464)	67	(316)
Stock-based compensation expense		0	(34)	1,345
Noncash (gain) loss on termination of leases		(4,602)	0	0
Cash flows from investing activities
Purchases of property, plant and equipment		0	(88)	(2,114)
Proceeds from sale of assets		$ 1,083	$ 3,952	$ 29

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustment		$ 0	$ (26,957)	$ 0
Income (loss) from discontinued operations		4,599	(66,748)	(153,582)
TS Biotechnology Holdings, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue			1,294	12,307
Operating expenses			896	116,091
Operating income (loss)			398	(103,784)
Gain on sale of discontinued operations			633
Loss on release of cumulative foreign currency translation adjustment	$ (26,957)		(26,957)
Other expense, net			(129)	(272)
Income (loss) before income taxes			(26,055)	(104,056)
Income tax (expense) benefit			(2)	3,005
Income (loss) from discontinued operations			(26,057)	(101,051)
EnviroFlight Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue			0	0
Operating expenses			0	10,794
Operating income (loss)			0	(10,794)
Gain on sale of discontinued operations			39
Loss on release of cumulative foreign currency translation adjustment			0
Other expense, net			0	0
Equity in net loss of affiliates			(38)	(4,314)
Income (loss) before income taxes			1	(15,108)
Income tax (expense) benefit			0	0
Income (loss) from discontinued operations			1	(15,108)
TS Biotechnology Holdings, LLC and EnviroFlight, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue			1,294	12,307
Operating expenses			896	126,885
Operating income (loss)			398	(114,578)
Gain on sale of discontinued operations			672
Loss on release of cumulative foreign currency translation adjustment			(26,957)	0
Other expense, net			(129)	(272)
Equity in net loss of affiliates			(38)	(4,314)
Income (loss) before income taxes			(26,054)	(119,164)
Income tax (expense) benefit			(2)	3,005
Income (loss) from discontinued operations		$ 0	(26,056)	(116,159)
Impairment charges				89,679
Related Parties, Aggregated | TS Biotechnology Holdings, LLC | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue			$ 436	$ 3,042

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Sep. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization			$ 13,761	$ 17,516	$ 24,896
Impairment of goodwill		$ 178	0	9,635	87,862
Impairment of other noncurrent assets			543	13,326	32,627
Gain on sale of discontinued operations			0	(672)	0
Loss on release of cumulative foreign currency translation adjustment			0	26,957	0
Unrealized and realized depreciation on equity securities and preferred stock, net	$ (7,348)		0	106	(7,833)
Equity in net loss of EnviroFlight			3	1,176	6,730
Stock-based compensation expense			13,904	18,366	18,950
Deferred income taxes			(167)	(156)	(3,674)
Investments in EnviroFlight			0	0	(3,713)
Purchases of property, plant and equipment			$ (7,247)	(7,527)	(37,883)
TS Biotechnology Holdings, LLC and EnviroFlight, LLC | Discontinued Operations, Disposed of by Sale
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization				0	5,107
Impairment of goodwill				0	58,042
Impairment of other noncurrent assets				0	31,637
Gain on sale of discontinued operations				(672)	0
Loss on release of cumulative foreign currency translation adjustment				26,957	0
Unrealized and realized depreciation on equity securities and preferred stock, net				106	458
Stock-based compensation expense				(1,346)	2,507
Deferred income taxes				0	(2,710)
Purchases of property, plant and equipment				(382)	(23,326)
EnviroFlight Sale | Discontinued Operations, Disposed of by Sale
Adjustments to reconcile net loss to net cash used in operating activities
Loss on release of cumulative foreign currency translation adjustment				0
Equity in net loss of EnviroFlight				38	4,314
Investments in EnviroFlight				$ 0	$ (2,000)

Discontinued Operations - Sum_4

Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net loss	$ (92,166)	$ (170,521)	$ (323,916)
Equity Method Investment, Nonconsolidated Investee or Group of Investees | EnviroFlight Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues		16	510
Operating expenses		92	9,159
Operating loss		(76)	(8,649)
Other, net		0	21
Net loss		$ (76)	$ (8,628)

Investments in Joint Ventures -

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended	12 Months Ended
	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2021USD ($)board_seat	Dec. 31, 2020USD ($)
Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Maximum additional capital contributions committed		$ 25,000,000
Additional capital contributions committed, remaining commitment			$ 4,225,000
Total number of seats on the joint venture's governing board | board_seat			5
Total number of seats on the joint venture's governing board, internally selected | board_seat			2
Total number of seats on the joint venture's governing board, externally selected | board_seat			3
Investor | Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Capital contribution		$ 25,000,000
Maximum additional capital contributions committed		25,000,000
Other accrued liabilities | Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ (428,000)	$ (425,000)
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 25,000,000	$ 25,000,000

Investments in Joint Ventures_2

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended	12 Months Ended
	Dec. 31, 2015USD ($)board_seat	Dec. 31, 2015USD ($)board_seat	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%	50.00%
Maximum additional capital contributions committed	$ 10,000,000	$ 10,000,000
Additional capital contributions committed, remaining commitment			$ 10,000,000
Total number of seats on the joint venture's governing board | board_seat	5	5
Total number of seats on the joint venture's governing board, internally selected | board_seat	1	1
Total number of seats on the joint venture's governing board, externally selected | board_seat	4	4
Investor | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%	50.00%
Capital contribution		$ 18,000,000
Maximum additional capital contributions committed	$ 10,000,000	10,000,000
All Investors | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution		4,000,000
Other accrued liabilities | Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ (435,000)	$ (435,000)
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000	$ 18,000,000

Collaboration and Licensing R_3

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jul. 31, 2020	Feb. 29, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			$ 103,873	$ 103,178	$ 90,722
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			506	21,208	14,059
Upfront and Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized from previously deferred balances			397	20,205	7,505
Alaunos Therapeutics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			100	200	2,171
Oragenics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			0	3,053	(564)
Revenue recognized from previously deferred balances	$ 2,823
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			0	0	2,596
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			0	0	1,217
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			388	17,810	3,713
Revenue recognized from previously deferred balances		$ 10,000
Harvest Start-Up Entities | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			0	0	4,862
Other revenues | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues			$ 18	$ 145	$ 64

Collaboration and Licensing R_4

Collaboration and Licensing Revenue - Additional Information (Details)

1 Months Ended

12 Months Ended

24 Months Ended

Jul. 31, 2020USD ($)

Mar. 31, 2020USD ($)

Feb. 29, 2020USD ($)

Dec. 31, 2015USD ($)

Mar. 31, 2014USD ($)

Oct. 31, 2012USD ($)

Dec. 31, 2021USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)product

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2020USD ($)

Nov. 30, 2020USD ($)

Collaboration Agreements [Line Items]

Deferred revenue

$ 27,465,000

$ 25,823,000

Required notice period for voluntary termination of collaborative agreement

90 days

Licensing agreement between Alaunos and Precigen 2018

Collaboration Agreements [Line Items]

License agreement, percentage of development costs for which responsible

20.00%

License agreement, percentage of operating profits to be received

20.00%

License agreement, annual fee

$ 100,000

License agreement, reimbursement of historical costs

$ 1,000,000

Milestone payments required upon successful achievement, aggregated

210,000,000

License agreement, royalty due, aggregated

$ 100,000,000

License agreement, percentage of sublicensing income

20.00%

Transition period during which costs will be reimbursed

1 year

License agreement, termination, period following triggering event

12 years

Collaboration and licensing agreements

Collaboration Agreements [Line Items]

Deferred revenue

$ 23,023,000

$ 23,420,000

Maximum | Licensing agreement between Alaunos and Precigen 2018

Collaboration Agreements [Line Items]

Milestone payments required upon successful achievement, per product

$ 52,500,000

License agreement, number of exclusively licensed products | product

4

Alaunos Therapeutics, Inc. | Licensing agreement between Alaunos and Precigen 2018

Collaboration Agreements [Line Items]

License agreement, percentage of development costs for which responsible

80.00%

License agreement, percentage of operating profits to be received

80.00%

License agreement, royalty due, aggregated

$ 50,000,000

Alaunos Therapeutics, Inc. | Collaboration and licensing agreements | Transition services

Collaboration Agreements [Line Items]

Deferred revenue

$ 1,855,000

Oragenics, Inc. | Collaboration and licensing agreements

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value of convertible promissory note

$ 5,000,000

Revenue recognized from previously deferred balances

$ 2,823,000

Intrexon Energy Partners, LLC | Collaboration and licensing agreements

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 25,000,000

$ 25,000,000

Required notice period for voluntary termination of collaborative agreement

90 days

Intrexon Energy Partners II, LLC | Collaboration and licensing agreements

Collaboration Agreements [Line Items]

Collaborative agreement, consideration received, value

$ 18,000,000

$ 18,000,000

Required notice period for voluntary termination of collaborative agreement

90 days

Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements

Collaboration Agreements [Line Items]

Deferred revenue

$ 6,993,000

Collaborative agreement, consideration received, value

$ 11,000,000

Castle Creek Biosciences, Inc. | Collaboration and licensing agreements

Collaboration Agreements [Line Items]

Revenue recognized from previously deferred balances

$ 10,000,000

Collaborative agreement, consideration received, value

$ 7,576,000

$ 7,612,000

Collaborative agreement, consideration received, cash

$ 3,750,000

Royalty rate as a percentage of net sales, tier 1

7.00%

Level of net sales at which royalty rate changes to tier 2

$ 25,000,000

Royalty rate as a percentage of net sales, tier 2

14.00%

Collaboration and Licensing R_5

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 27,465	$ 25,823
Current portion of deferred revenue	4,442	2,800
Long-term portion of deferred revenue	23,023	23,023
Prepaid product and service revenues
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,229	2,126
Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	213	277
Collaboration and licensing agreements
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 23,023	$ 23,420

Collaboration and Licensing R_6

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 23,420
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	$ 23,023
Intrexon Energy Partners, LLC | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		8,362
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)	2 years 2 months 12 days
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	$ 8,362
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		12,843
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)	2 years 10 months 24 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	$ 12,843
Castle Creek Biosciences, Inc. | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		379
Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)	0 years
Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	$ 0
Other | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 1,836
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)	2 years 9 months 18 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	$ 1,818

Collaboration and Licensing R_7

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details) - Upfront and Milestone Payments $ in Thousands	Dec. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 23,420
Intrexon Energy Partners, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	8,362
Intrexon Energy Partners II, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	12,843
Castle Creek Biosciences, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	379
Other
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 1,836

Short-term and Long-term Inve_3

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 121,133	$ 48,312
Gross Unrealized Gains	0	14
Gross Unrealized Losses	(331)	(1)
Aggregate Fair Value	120,802	48,325
United States government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	121,036	48,048
Gross Unrealized Gains	0	14
Gross Unrealized Losses	(331)	(1)
Aggregate Fair Value	120,705	48,061
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	97	264
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 97	$ 264

Short-term and Long-term Inve_4

Short-term and Long-term Investments - Contractual Obligation, Fiscal year Maturity (Details) $ in Thousands	Dec. 31, 2021USD ($)
Investments, Debt and Equity Securities [Abstract]
Due within one year	$ 72,240
After one year through two years	48,562
Total	$ 120,802

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 120,802	$ 48,325
United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	120,705	48,061
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	97	264
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Quoted Prices in Active Markets (Level 1) | United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Quoted Prices in Active Markets (Level 1) | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	120,802	48,325
Significant Other Observable Inputs (Level 2) | United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	120,705	48,061
Significant Other Observable Inputs (Level 2) | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	97	264
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Significant Unobservable Inputs (Level 3) | United States government debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	0	0
Significant Unobservable Inputs (Level 3) | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 31, 2018
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value	$ 0	$ 0	$ 585,000
3.5% Convertible Notes Due 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of convertible debt	160,000,000	165,000,000
Carrying value of convertible debt	$ 179,882,000	$ 168,147,000		$ 143,723,000

Fair Value Measurements - Chang

Fair Value Measurements - Change in Fair Value Level 3 Liability (Details) - Significant Unobservable Inputs (Level 3) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2019	$ 585
Change in fair value of contingent consideration recognized in selling, general, and administrative expenses	(585)
Balance at December 31, 2020	$ 0

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory [Line Items]
Inventory	$ 13,261	$ 11,359
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	2,588	2,060
Work in process
Inventory [Line Items]
Inventory	2,564	2,348
Livestock
Inventory [Line Items]
Inventory	6,310	5,047
Feed
Inventory [Line Items]
Inventory	$ 1,799	$ 1,904

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 11,118	$ 9,844
Buildings and building improvements	12,896	12,088
Furniture and fixtures	1,162	1,228
Equipment	33,584	31,150
Leasehold improvements	4,822	6,260
Breeding stock	1,000	868
Computer hardware and software	5,131	5,684
Construction and other assets in progress	3,824	2,754
Property, plant and equipment, gross	73,537	69,876
Less: Accumulated depreciation and amortization	(39,222)	(34,952)
Property, plant and equipment, net	$ 34,315	$ 34,924

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019reporting_unit	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Property, Plant and Equipment [Abstract]
Depreciation expense		$ 6,202	$ 7,449	$ 8,222
Impairment of long-lived assets held-for-use		$ 543	$ 920	$ 448
Number of reporting units closed | reporting_unit	2

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill
Beginning of year	$ 54,363
End of year	54,148	$ 54,363
Continuing Operations
Goodwill
Beginning of year	54,363	54,119
Foreign currency translation adjustments	(215)	244
End of year	$ 54,148	$ 54,363

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Additional Information (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019USD ($)reporting_unit	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Goodwill [Line Items]
Accumulated goodwill impairment losses		$ 43,643	$ 43,643
Impairment of goodwill	$ 178	0	9,635	$ 87,862
Number of reporting units closed | reporting_unit	2
Amortization expense		$ 7,559	$ 7,593	7,920
Trans Ova
Goodwill [Line Items]
Impairment of goodwill				$ 29,642

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	$ 108,123	$ 113,677
Accumulated Amortization	(54,008)	(48,281)
Finite-lived intangible assets, net, total	54,115	65,396
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	91,373	96,927
Accumulated Amortization	(38,630)	(34,412)
Finite-lived intangible assets, net, total	52,743	62,515
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	10,850	10,850
Accumulated Amortization	(10,252)	(9,340)
Finite-lived intangible assets, net, total	598	1,510
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	5,900	5,900
Accumulated Amortization	(5,126)	(4,529)
Finite-lived intangible assets, net, total	$ 774	$ 1,371
Weighted Average Useful Life (Years) | Patents, developed technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	15 years 10 months 24 days
Weighted Average Useful Life (Years) | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	6 years 4 months 24 days
Weighted Average Useful Life (Years) | Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	8 years 4 months 24 days

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 6,597
2023	5,431
2024	5,121
2025	5,108
2026	5,108
Thereafter	26,750
Finite-lived intangible assets, net, total	$ 54,115	$ 65,396

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Credit Facility - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of credit facility, interest rate at period end	3.25%
Line of credit outstanding	$ 0	$ 0
Line of credit facility, current borrowing capacity	5,000,000
Exemplar Genetics, LLC | American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	4.00%
Line of credit outstanding	$ 0	$ 0
Minimum | Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long-term debt	$ 183,151	$ 171,882
Less current portion	402	360
Long-term debt, less current portion	182,749	171,522
Convertible debt
Debt Instrument [Line Items]
Long-term debt	179,882	168,147
Notes payable
Debt Instrument [Line Items]
Long-term debt	3,217	3,655
Other
Debt Instrument [Line Items]
Long-term debt	$ 52	$ 80

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended			12 Months Ended
	Oct. 31, 2020shares	Sep. 30, 2020shares	Jul. 31, 2018USD ($)day$ / shares	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)
Debt Instrument [Line Items]
Proceeds from long-term debt, net of issuance costs				$ 0	$ 0	$ 376,000
Deferred income taxes				(167,000)	(156,000)	(3,674,000)
Interest payable				3,500,000
Long-term debt				183,151,000	171,882,000
Convertible debt
Debt Instrument [Line Items]
Long-term debt				$ 179,882,000	168,147,000
Convertible debt | Precigen ActoBio, Inc. | Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage								3.00%
Interest expense					616,000	$ 921,000
Notes payable to banks | Trans Ova Genetics, LC | American State Bank
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				3.95%
Long-term debt				$ 3,217,000
Debt instrument, periodic payment				39,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount			$ 200,000,000	200,000,000
Proceeds from long-term debt, net of issuance costs			193,958,000
Debt issuance costs			$ 6,042,000
Debt instrument, interest rate, stated percentage			3.50%
Conversion rate			58.6622
Principal amount used in conversion			$ 1,000
Conversion price (in usd per share) | $ / shares			$ 17.05
Debt instrument redemption price, percentage			100.00%
Carrying value of convertible debt			$ 143,723,000	$ 179,882,000	$ 168,147,000
Adjustments to additional paid in capital, equity component of convertible debt			50,235,000
Deferred income taxes			$ 13,367,000
Effective interest rate on convertible notes				11.02%
Convertible notes, unamortized discount and issuance costs				$ 20,118,000
3.5% Convertible Notes Due 2023 | Minimum
Debt Instrument [Line Items]
Common stock price trading days | day			20
Common stock price consecutive trading days | day			30
Percentage of common share price over conversion price for conversion			130.00%
3.5% Convertible Notes Due 2023 | Maximum
Debt Instrument [Line Items]
Common stock price trading days | day			5
Common stock price consecutive trading days | day			5
Debt instrument redemption price, percentage			98.00%
Merck Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount							$ 25,000,000
Common stock issued upon conversion of long-term debt (in shares) | shares	6,758,400
ActoBio Notes
Debt Instrument [Line Items]
Common stock issued upon conversion of long-term debt (in shares) | shares		6,293,402
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio, Inc.
Debt Instrument [Line Items]
Aggregate principal amount								$ 30,000,000

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Cash interest expense	$ 7,000	$ 7,000	$ 7,000
Non-cash interest expense	11,735	10,587	9,459
Total interest expense	$ 18,735	$ 17,587	$ 16,459

Lines of Credit and Long-Term_7

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 402
2023	200,364
2024	379
2025	394
2026	410
Thereafter	1,320
Total	$ 203,269

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (96,925)	$ (103,855)	$ (171,264)
Domestic
Income Tax [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(93,540)	(97,313)	(167,990)
Foreign
Income Tax [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (3,385)	$ (6,542)	$ (3,274)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
United States federal income taxes:
Deferred	$ 37	$ 37	$ (561)
Foreign income taxes:
Current	7	74	34
Deferred	(215)	(204)	(230)
State income taxes:
Deferred	11	11	(173)
Total income tax benefit from continuing operations	$ (160)	$ (82)	$ (930)

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Computed statutory income tax benefit from continuing operations	$ (20,354)	$ (21,810)	$ (35,965)
State and provincial income tax benefit, net of federal income taxes	(3,993)	(5,167)	(5,494)
Nondeductible stock based compensation	832	5,709	10,303
Nondeductible officer compensation	1,459	728	595
Impairment of goodwill	0	0	273
Research and development tax incentives	(958)	(524)	(1,772)
Acquisition and internal restructuring transaction costs	0	0	260
United States-foreign rate differential	(32)	(21)	(76)
Other, net	(46)	(306)	(72)
Income tax reconciliation income tax benefit before valuation allowance, total	(23,092)	(21,391)	(31,948)
Change in valuation allowance for deferred tax assets	22,932	21,309	31,018
Total income tax benefit from continuing operations	$ (160)	$ (82)	$ (930)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets
Allowance for doubtful accounts	$ 1,506	$ 1,816
Inventory	370	289
Equity securities and investments in affiliates	570	570
Property, plant and equipment	0	1,882
Intangible assets	69,679	74,981
Accrued liabilities	3,090	1,834
Lease liabilities	2,839	6,140
Stock-based compensation	15,227	16,402
Deferred revenue	7,300	7,423
Research and development tax credits	11,168	10,210
Net operating, capital loss, and interest expense carryforwards	301,791	275,519
Total deferred tax assets	413,540	397,066
Less: Valuation allowance	408,396	387,348	$ 349,008	$ 292,217
Net deferred tax assets	5,144	9,718
Deferred tax liabilities
Property, plant and equipment	250	0
Right-of-use assets	2,735	5,011
Long-term debt	4,698	7,604
Total deferred tax liabilities	7,683	12,615
Net deferred tax liabilities included in continuing operations	$ (2,539)	$ (2,897)

Income Taxes - Summary of Valua

Income Taxes - Summary of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Valuation Allowance
Valuation allowance at beginning of year	$ 387,348	$ 349,008	$ 292,217
Deconsolidation of AquaBounty	0	0	(3,504)
Establishment of deferred taxes for subsidiaries included in discontinued operations	0	0	8,592
Current year continuing operations	22,932	21,309	31,018
Discontinued operations treated as asset sales	0	7,977	10,585
Discontinued operations related to MBP Titan	(1,186)	8,019	9,663
Foreign currency translation adjustment	(698)	1,035	(75)
Valuation allowance at end of year	408,396	387,348	349,008
Adoption of ASC 842
Valuation Allowance
Adoption of ASC 842	$ 0	$ 0	$ 512

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Federal and state research and development tax credits	$ 11,168	$ 10,210
Accumulated deficit	1,915,556	$ 1,823,390
Foreign Subsidiaries
Operating Loss Carryforwards [Line Items]
Accumulated deficit	23,100
Domestic
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition	42,100
Operating loss carryforwards	856,400
Deferred tax assets, capital loss carryforwards	212,500
Federal and state research and development tax credits	11,100
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	75,700
Generated after 2017 | Domestic
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 603,700

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 31, 2020	Jan. 31, 2021	Mar. 31, 2019	Jul. 31, 2018	Dec. 31, 2019
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares		17,250,000
Value of shares issued in public or private offering		$ 121,045			$ 6,611
Shares issued in share lending agreement, shares				7,479,431
Share lending agreement, length of time for shares to be returned upon termination				5 days
Shares issued, price per share				$ 13.37
TS Biotechnology Holdings, LLC
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares	5,972,696
Value of shares issued in public or private offering	$ 35,000
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Value of shares issued in public or private offering			$ 6,611

Shareholders' Equity - Componen

Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity			$ 71,711	$ 378,722
Total accumulated other comprehensive income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ 203	$ 3,997	$ (27,468)	$ (28,612)
Unrealized gain (loss) on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	(331)	13
Income on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ 534	$ 3,984

Share-Based Payments - Schedule

Share-Based Payments - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	$ 13,904	$ 18,366	$ 18,950
Cost of products
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	30	10	20
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	172	134	220
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	2,735	1,815	3,478
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	10,967	17,787	11,380
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	$ 0	$ (1,380)	$ 3,852

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 28, 2022	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, terms of award				ten
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lock-up period			3 years
Compensation arrangement with individual, annual cash retainer		$ 100
Precigen Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)				12,260,187	11,255,896	9,022,282	11,093,063
Restricted stock units outstanding (in shares)				468,481	1,727,712	1,781,982	970,341
Unrecognized compensation costs related to unvested stock option awards				$ 15,745
Weighted average grant date fair value of options granted (in usd per share)				$ 5.57	$ 2.98	$ 3.79
Aggregate intrinsic value of options exercised				$ 225	$ 51	$ 66
Granted (in shares)				2,058,820	5,693,498	1,556,575
Precigen Stock Option Plans | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	3,103,500
Share​ based ​compensation ​arrangement​ by ​share based ​payment ​award, options, ​grant date fair value	$ 5,300
Precigen Stock Option Plan 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)				0
Options outstanding (in shares)				29,683
Precigen Stock Option Plan 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)				5,813,233
Options outstanding (in shares)				11,164,186
Number of authorized awards (in shares)				27,000,000
Restricted stock units outstanding (in shares)				306,360
Precigen Stock Option Plan 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)				1,974,662
Options outstanding (in shares)				1,066,318
Number of authorized awards (in shares)				5,000,000
Restricted stock units outstanding (in shares)				162,121
Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly base salary			$ 200
Selling, general and administrative | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, expense				$ 680	$ 767	$ 1,868
Options | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual stock option grant, grant date fair value		250
Options | Precigen Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, terms of award				ten-year
Vesting period of equity grant				4 years
Recognized over weighted-average period				2 years 6 months
Restricted stock units | Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation arrangement with individual, annual RSU grant, grant date fair value		$ 250
Restricted stock units | Precigen Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized over weighted-average period				6 months
Unrecognized compensation costs related to restricted stock unit awards				$ 1,145

Share-Based Payments - Schedu_2

Share-Based Payments - Schedule of Stock Option Activity (Details) - Precigen Stock Option Plans - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Shares
Balances at beginning of period (in shares)	11,255,896	9,022,282	11,093,063
Granted (in shares)	2,058,820	5,693,498	1,556,575
Exercised (in shares)	(127,883)	(30,061)	(19,887)
Forfeited (in shares)	(305,293)	(976,324)	(1,236,326)
Expired (in shares)	(621,353)	(2,453,499)	(2,371,143)
Balances at period end (in shares)	12,260,187	11,255,896	9,022,282	11,093,063
Weighted Average Exercise Price (usd per share)
Balances at beginning of period (in usd per share)	$ 15.53	$ 21.94	$ 27.95
Granted (in usd per share)	7.59	10.03	6.52
Exercised (in usd per share)	(4.75)	(3.88)	(3.17)
Forfeited (in usd per share)	(7.02)	(15.47)	(24.92)
Expired (in usd per share)	(24.61)	(26.53)	(38.53)
Balances at period end (in usd per share)	$ 14.06	15.53	$ 21.94	$ 27.95
Additional Disclosures
Exercisable at period end (in shares)	7,078,840
Options exercisable, weighted average exercise price (in usd per share)	$ 16.69	$ 19.61
Balances at period end, weighted average remaining contractual period	6 years 9 months 14 days	7 years 3 months	6 years 1 month 6 days	6 years 9 months 21 days
Exercisable at period end, weighted average remaining contractual period	5 years 7 months 2 days

Share-Based Payments - Summary

Share-Based Payments - Summary of Information About Stock Options Outstanding (Details) - Precigen Stock Option Plans - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, number of options (in shares)	12,260,187	11,255,896
Options outstanding, weighted average exercise price (in usd per share)	$ 14.06	$ 15.53	$ 21.94	$ 27.95
Options outstanding, weighted average remaining life (in years)	6 years 9 months 14 days	7 years 3 months
Options outstanding, aggregate intrinsic value	$ 1,329	$ 19,482
Options exercisable, number of options (in shares)	7,078,840	5,437,667
Options exercisable, weighted average exercise price (in usd per share)	$ 16.69	$ 19.61
Options exercisable, weighted average remaining life (in years)	5 years 7 months 2 days	5 years 7 months 9 days
Options exercisable, aggregate intrinsic value	$ 1,327	$ 9,707
Price range 1
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 1.55	$ 1.55
Stock options, exercise price range, upper limit (in usd per share)	$ 5.95	$ 5.95
Options outstanding, number of options (in shares)	3,290,348	3,259,685
Options outstanding, weighted average exercise price (in usd per share)	$ 4.64	$ 4.63
Options outstanding, weighted average remaining life (in years)	8 years 2 months 4 days	8 years 11 months 1 day
Options outstanding, aggregate intrinsic value	$ 1,329	$ 18,157
Options exercisable, number of options (in shares)	2,031,348	1,271,310
Options exercisable, weighted average exercise price (in usd per share)	$ 4.15	$ 3.11
Options exercisable, weighted average remaining life (in years)	7 years 11 months 23 days	8 years 8 months 23 days
Options exercisable, aggregate intrinsic value	$ 1,327	$ 9,018
Price range 2
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 6.01	$ 6.06
Stock options, exercise price range, upper limit (in usd per share)	$ 11.90	$ 15.09
Options outstanding, number of options (in shares)	3,568,102	2,261,216
Options outstanding, weighted average exercise price (in usd per share)	$ 9.69	$ 11.01
Options outstanding, weighted average remaining life (in years)	8 years 5 months 15 days	8 years 2 months 23 days
Options outstanding, aggregate intrinsic value	$ 0	$ 1,325
Options exercisable, number of options (in shares)	833,104	345,788
Options exercisable, weighted average exercise price (in usd per share)	$ 9.79	$ 9.09
Options exercisable, weighted average remaining life (in years)	7 years 10 months 24 days	4 years 9 months 3 days
Options exercisable, aggregate intrinsic value	$ 0	$ 689
Price range 3
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 12.01	$ 15.80
Stock options, exercise price range, upper limit (in usd per share)	$ 20.94	$ 20.94
Options outstanding, number of options (in shares)	3,068,340	3,028,309
Options outstanding, weighted average exercise price (in usd per share)	$ 18.59	$ 18.85
Options outstanding, weighted average remaining life (in years)	6 years 1 month 2 days	7 years 4 months 17 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,880,991	1,216,258
Options exercisable, weighted average exercise price (in usd per share)	$ 19.16	$ 19.82
Options exercisable, weighted average remaining life (in years)	4 years 11 months 4 days	5 years 7 months 13 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 4
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 21.13	$ 21.13
Stock options, exercise price range, upper limit (in usd per share)	$ 45.69	$ 36.84
Options outstanding, number of options (in shares)	2,332,393	2,303,371
Options outstanding, weighted average exercise price (in usd per share)	$ 28.06	$ 26.33
Options outstanding, weighted average remaining life (in years)	3 years 2 months 19 days	4 years 3 months 25 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	2,332,393	2,200,996
Options exercisable, weighted average exercise price (in usd per share)	$ 28.06	$ 26.52
Options exercisable, weighted average remaining life (in years)	3 years 2 months 19 days	4 years 2 months 19 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 5
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 47.35	$ 37.88
Stock options, exercise price range, upper limit (in usd per share)	$ 47.35	$ 47.35
Options outstanding, number of options (in shares)	1,004	403,315
Options outstanding, weighted average exercise price (in usd per share)	$ 47.35	$ 42.26
Options outstanding, weighted average remaining life (in years)	3 years 6 months 3 days	4 years 3 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,004	403,315
Options exercisable, weighted average exercise price (in usd per share)	$ 47.35	$ 42.26
Options exercisable, weighted average remaining life (in years)	3 years 6 months 3 days	4 years 3 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0

Share-Based Payments - Schedu_3

Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - Precigen Stock Option Plans - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Restricted Stock Units
Balances at beginning of period (in shares)	1,727,712	1,781,982	970,341
Granted (in shares)	462,019	3,157,390	2,278,460
Vested (in shares)	(1,624,013)	(2,802,593)	(1,159,165)
Forfeited (in shares)	(97,237)	(409,067)	(307,654)
Balances at period end (in shares)	468,481	1,727,712	1,781,982	970,341
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 6.11	$ 8.71	$ 13.82
Granted (in usd per share)	7.87	3.09	6.59
Vested (in usd per share)	(5.76)	(3.99)	(8.74)
Forfeited (in usd per share)	(8.96)	(8.59)	(8.99)
Balances at period end (in usd per share)	$ 8.47	$ 6.11	$ 8.71	$ 13.82
Additional Disclosures
Balances at period end, weighted average remaining contractual period	3 months 29 days	5 months 1 day	1 year 2 months 26 days	1 year 5 months 4 days

Operating Leases - Additional I

Operating Leases - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	9 years

Operating Leases - Components o

Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease costs	$ 3,264	$ 3,578	$ 3,821
Short-term lease costs	1,949	1,763	2,042
Variable lease costs	853	842	845
Lease costs	$ 6,066	$ 6,183	$ 6,708

Operating Leases - Maturities o

Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 2,680
2023	2,304
2024	2,355
2025	2,263
2026	1,787
Thereafter	4,638
Total	16,027
Present value adjustment	(4,974)
Total	11,053
Current portion of lease liabilities	1,551	$ 2,657
Long-term portion of operating lease liabilities	$ 9,502	$ 7,744

Operating Leases - Lease Terms

Operating Leases - Lease Terms and Discount Rates (Details)	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted average remaining lease term (years)	6 years 7 months 24 days	4 years 2 months 15 days
Weighted average discount rate	10.99%	10.27%

Operating Leases - Other Inform

Operating Leases - Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$ 3,598	$ 4,012	$ 3,877
Operating lease right-of-use assets obtained in exchange for new lease liabilities (includes new leases or modifications of existing leases)	$ 4,868	$ 417	$ 1,137

Commitments and Contingencies -

Commitments and Contingencies - Contingencies - Additional Information (Details) $ in Thousands	Dec. 01, 2020claim	Sep. 30, 2020USD ($)	Dec. 31, 2021patent	Nov. 30, 2020claim
XY, LLC | Licensing and patent infringement suit
Loss Contingencies [Line Items]
Loss contingency, claims settled, number	1
Claims pending resolution				2
Loss Contingency, Number Of Patents At Issue | patent			5
Securities And Exchange Commission | Methane Bioconversion Platform Disclosures
Loss Contingencies [Line Items]
Payments for legal settlements | $		$ 2,500

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended					12 Months Ended
	Nov. 30, 2021	Dec. 31, 2020	Jan. 31, 2020	Dec. 31, 2019	Oct. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 30, 2020
Related Party Transaction [Line Items]
Shares issued as payment for services								$ 10,446
Proceeds from sales of equity securities					$ 21,587	$ 0	$ 0	23,456
Deferred revenue		$ 25,823				27,465	25,823
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc.
Related Party Transaction [Line Items]
Investments in affiliates									$ 326
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Deferred revenue		$ 23,420				23,023	23,420
Harvest Intrexon Enterprise Fund I, LP
Related Party Transaction [Line Items]
Stock issued in conjunction with settlement agreement, shares		2,117,264
Shares issued in conjunction with settlement agreement		$ 18,103
Loss related to litigation settlement		$ 11,436
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements
Related Party Transaction [Line Items]
Deferred revenue									$ 6,993
Third Security
Related Party Transaction [Line Items]
Expense for services						100	159	$ 26
Common stock calculation period								30 days
Shares issued as payments for services (in shares)								1,606,062
Shares issued as payment for services								$ 8,233
Sublease rental income						$ 75	$ 83	89
Cash received on contract termination	$ 143
Castle Creek Biosciences, Inc.
Related Party Transaction [Line Items]
Proceeds from sales of equity securities				$ 1,280
Proceeds from convertible preferred shares and convertible note			$ 3,311
Changes in fair value, gain								3,222
Common Stock | Third Security
Related Party Transaction [Line Items]
Expense for services								$ 800
Third Security | Executive Chairman
Related Party Transaction [Line Items]
Ownership interest						100.00%

Segments - Adjusted EBITDA by R

Segments - Adjusted EBITDA by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ (21,436)	$ (17,844)	$ (52,475)
Biopharmaceuticals
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	(45,754)	(35,378)	(44,552)
Exemplar
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	6,898	4,004	(1,586)
Trans Ova
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	17,420	13,530	(2,836)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ 0	$ 0	$ (3,501)

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ (21,436)	$ (17,844)	$ (52,475)
Other expenses:
Depreciation and amortization	(13,761)	(17,516)	(24,896)
Loss on settlement agreement	0	(11,436)	0
Stock-based compensation expense	(13,904)	(18,366)	(18,950)
Equity in net loss of affiliates	(3)	(1,176)	(6,730)
Other	(24)	(35)	(837)
Loss before income taxes	(96,925)	(103,855)	(171,264)
Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	397	20,205	7,505
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	5,774	389	11,886
Operating segments | Add recognition of previously deferred revenue associated with upfront and milestone payments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	2,034	25,005	14,721
Corporate And Reconciling Items [Member]
Other expenses:
Interest expense	(18,891)	(18,400)	(17,666)
Depreciation and amortization	(13,761)	(15,042)	(16,142)
Loss from disposals of assets	(614)	(4,375)	(3,018)
Impairment losses	(543)	(920)	(30,810)
Loss on settlement agreement	0	(11,436)	0
Stock-based compensation expense	(13,904)	(19,746)	(15,098)
Adjustment related to accrued bonuses paid in equity awards	0	2,833	0
Equity in net loss of affiliates	(3)	(1,138)	(2,416)
Other	(19)	11	67
Unallocated corporate costs
Other expenses:
Loss before income taxes	(33,506)	(37,479)	(46,007)
Eliminations
Other expenses:
Loss before income taxes	(2,056)	(5,713)	(14,306)
Segment Adjusted EBITDA for reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA for operating segments	$ (21,436)	$ (17,844)	$ (48,974)

Segments - Revenues by Reportab

Segments - Revenues by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenues from external customers	$ 103,873	$ 103,178	$ 90,722
Total segment revenues from reportable segments
Segment Reporting Information [Line Items]
Revenues	105,939	108,261	96,165
Operating segments
Segment Reporting Information [Line Items]
Revenues from external customers	103,873	103,124	86,762
Revenues	105,939	108,261	101,049
Operating segments | Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues from external customers	922	21,780	6,259
Revenues	2,559	26,577	19,167
Operating segments | Exemplar
Segment Reporting Information [Line Items]
Revenues from external customers	13,345	10,158	6,958
Revenues	13,345	10,158	6,965
Operating segments | Trans Ova
Segment Reporting Information [Line Items]
Revenues from external customers	89,606	71,186	68,672
Revenues	90,035	71,526	70,033
Operating segments | All Other
Segment Reporting Information [Line Items]
Revenues from external customers			4,873
Revenues			4,884
Eliminations
Segment Reporting Information [Line Items]
Revenues	2,066	5,137	14,287
Eliminations | Biopharmaceuticals
Segment Reporting Information [Line Items]
Revenues	1,637	4,797	12,908
Eliminations | Exemplar
Segment Reporting Information [Line Items]
Revenues	0	0	7
Eliminations | Trans Ova
Segment Reporting Information [Line Items]
Revenues	429	340	1,361
Eliminations | All Other
Segment Reporting Information [Line Items]
Revenues			11
Other revenues, including from other operating segments
Segment Reporting Information [Line Items]
Revenues	0	54	9,064
Elimination of intersegment revenues
Segment Reporting Information [Line Items]
Revenues	$ (2,066)	$ (5,137)	$ (14,507)

Segments - Goodwill (Details)

Segments - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill
Beginning of year	$ 54,363
End of year	54,148	$ 54,363
Operating segments
Goodwill
Beginning of year	54,363	54,119
Foreign currency translation adjustments	(215)	244
End of year	54,148	54,363
Operating segments | Biopharmaceuticals
Goodwill
Beginning of year	17,693	17,449
Foreign currency translation adjustments	(215)	244
End of year	17,478	17,693
Operating segments | Exemplar
Goodwill
Beginning of year	20,076	20,076
Foreign currency translation adjustments	0	0
End of year	20,076	20,076
Operating segments | Trans Ova
Goodwill
Beginning of year	16,594	16,594
Foreign currency translation adjustments	0	0
End of year	$ 16,594	$ 16,594

Segments - Additional Informati

Segments - Additional Information (Details) - Non-US - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Long-lived assets	$ 4,463	$ 5,908
Revenues	$ 530	$ 595	$ 1,401

Defined Contribution Plans - Ad

Defined Contribution Plans - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined contribution plans, cost recognized	$ 887	$ 873	$ 1,186